Serum Globulins

All categories

Name: Serum Globulins
Accession Number: DBCAT000018
Description: All blood proteins except albumin ( = SERUM ALBUMIN, which is not a globulin) and FIBRINOGEN (which is not in the serum). The serum globulins are subdivided into ALPHA-GLOBULINS; BETA-GLOBULINS; and GAMMA-GLOBULINS on the basis of their electrophoretic mobilities. (From Dorland, 28th ed)
Drugs: Drug Drug Description
Abagovomab Abagovomab is under investigation in clinical trial NCT00418574 (Efficacy Multicentre Trial of Immunotherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients).
Abatacept A disease-modifying antirheumatic drug (DMARD) used in the management of rheumatic conditions, such as rheumatoid or psoriatic arthritis, and for the prophylaxis of acute graft-versus-host disease.
Abciximab A monoclonal anti-glycoprotein IIb/IIIa receptor antibody used to prevent thrombosis during percutaneous coronary intervention.
Abelacimab Abelacimab is under investigation in clinical trial NCT04755283 (Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation).
Abituzumab Abituzumab has been used in trials studying the treatment of Prostate Cancer Metastatic.
Abrilumab Abrilumab is under investigation in clinical trial NCT01290042 (Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.).
Acimtamig Acimtamig is a tetravalent bispecific chimeric anti-human CD30 x anti-human CD16A recombinant antibody construct.
Actoxumab Actoxumab is under investigation in clinical trial NCT01241552 (A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)).
Adakitug Investigated for use/treatment in autoimmune diseases and inflammatory disorders (unspecified).
Adalimumab A monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.
Adecatumumab Investigated for use/treatment in breast cancer and prostate cancer.
Aducanumab A monoclonal antibody indicated in the treatment of Alzheimer's disease.
Afelimomab Investigated for use/treatment in sepsis and septicemia.
AGS-16C3F AGS 16C3F is an intravenously administered, anti-ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) antibody-drug conjugate. AGS-16C3F is under investigation in clinical trial NCT02639182 (A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell...
Alefacept A recombinant fusion protein that binds CD2 and is used treat moderate to severe plaque psoriasis.
Alemtuzumab A monoclonal anti-CD52 antibody used in the treatment of B-cell chronic lymphocytic leukemia and relapsing forms of multiple sclerosis.
Alirocumab A PCSK9 inhibitor used as an adjunct to manage heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in patients who require additional lowering of LDL-cholesterol (LDL-C).
Alpha-1-proteinase inhibitor A purified form of human alpha-1 proteinase inhibitor used to treat emphysema patients with associated alpha-1 proteinase inhibitor deficiency.
Amatuximab Amatuximab has been used in trials studying the treatment and basic science of Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Pancreatic Cancer, and Mesothelioma, Malignant, among others.
AMG 108 Investigated for use/treatment in osteoarthritis and rheumatoid arthritis.
Amivantamab An EGF and MET receptor targeted antibody indicated in the treatment of non-small cell lung cancer with an EGFR 20 exon insertion mutation.
Amubarvimab Amubarvimab (BRII-196) was under investigation in clinical trials (NCT04691180 and NCT04787211) to treat COVID-19, focusing on its safety, tolerability, and efficacy.
Andecaliximab GS-5745 has been used in trials studying the treatment of Tumors, Breast Cancer, Crohn's Disease, Colorectal Cancer, and Pancreatic Cancer, among others.
Anetumab ravtansine Anetumab ravtansine is under investigation in clinical trial NCT03455556 (Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer).
Anifrolumab A monoclonal antibody that inhibits type 1 interferon receptors, indicated in the treatment of moderate to severe systemic lupus erythematosus.
Anrukinzumab Anrukinzumab has been used in trials studying the diagnostic of Asthma.
Ansuvimab A fully human monoclonal IgG1 antibody directed against the GP1,2 surface protein of Zaire ebolavirus that is an effective treatment for Ebola virus disease.
Anthrax immune globulin human An immunizing agent used for the treatment of inhalational anthrax in adult and pediatric patients in combination with antibacterial agents.
Anti-SARS-CoV-2 immunoglobulin Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) is obtained from the plasma of patients who recover from COVID-19 and develop neutralizing antibodies. Anti-coronavirus immunoglobulin is derived from COVID-19 convalescent plasma(https://go.drugbank.com/drugs/DB15692) but contains...
Anti-SARS-CoV-2 REGN-COV2 Anti-SARS-COV-2 REGN-COV2 is a combination of novel antibodies designed by Regeneron for both the prevention and treatment of SARS-COV-2, the virus that causes COVID-19. This drug is a combination of...
Antilymphocyte immunoglobulin (horse) A primarily IgG immune globulin used to manage allograft rejection in renal transplant patients.
Antithrombin III human An alpha-2-glycoprotein used to prevent thromboembolisms in patients with hereditary antithrombin III deficiency.
Antithymocyte immunoglobulin (rabbit) A purified form of rabbit anti-thymocyte antibodies used for immunosuppression in patients receiving kidney transplants.
Anvatabart opadotin Not Annotated
Apitegromab Apitegromab is under investigation in clinical trial NCT03921528 (An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy).
Apolizumab Investigated for use/treatment in lymphoma (non-hodgkin's), leukemia (lymphoid), and solid tumors.
Apomab Apomab is under investigation in clinical trial NCT00851136 (A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and...
Aprutumab ixadotin Not Annotated
Arcitumomab Not Annotated
Ascrinvacumab Ascrinvacumab has been used in trials studying the treatment and basic science of Neoplasms, Advanced Solid Tumors, Carcinoma, Hepatocellular, and Malignant Pleural Mesothelioma.
Asfotase alfa An enzyme replacement therapy used for the treatment of perinatal/infantile and juvenile onset hypophosphatasia (HPP).
Asg-5me Not Annotated
ASI402 Investigated for use/treatment in breast cancer.
Astegolimab Astegolimab is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).
Asunercept Asunercept is under investigation in clinical trial NCT02853565 (A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme).
Atezolizumab A monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy.
Atibuclimab Investigated for use/treatment in sepsis and septicemia and pneumonia.
Atoltivimab Part of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells.
Av-203 Not Annotated
Avdoralimab Avdoralimab is under investigation in clinical trial NCT04333914 (Prospective Study in Patients With Advanced or Metastatic Cancer and Sars-cov-2 Infection).
AVE9633 Investigated for use/treatment in leukemia (myeloid).
Avelumab An anti-PD-L1 monoclonal antibody used to treat metastatic merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma.
AVP-21D9 AVP-21D9 is a fully human anthrax monoclonal antibody that is being investigated as an anthrax antitoxin.
AVX-470 AVX-470 is an anti-tumor necrosis factor (TNF) polyclonal antibody (bovine).
Axatilimab A monoclonal antibody targeting CSF-1R to reduce pathogenic macrophage activity in patients with chronic graft-versus-host disease.
AZD7442 AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. It was developed by AstraZeneca with the...
Balstilimab Not Annotated
Bamlanivimab A neutralizing human IgG1κ monoclonal antibody against the SARS-CoV-2 spike (S) protein for use in patients aged 12 and over at high risk of developing severe COVID-19.
Bapineuzumab Bapineuzumab has been investigated for the treatment of Alzheimer's Disease.
Basiliximab A monoclonal anti-C25 antibody (interleukin-2 receptor alpha subunit) used as immunosuppressive therapy in kidney transplant patients.
Batoclimab Batoclimab is under investigation in clinical trial NCT04428255 (A Clinical Study on the Efficacy and Safety of HBM9161 in Patients With ITP).
Bavituximab Investigated for use/treatment in breast cancer, cancer/tumors (unspecified), HIV infection, hepatitis (viral, C), and solid tumors.
Bebtelovimab A human IgG1κ monoclonal antibody targeted against the spike protein of SARS-CoV-2 which is used in the treatment of mild-to-moderate COVID-19.
Bectumomab Investigated for use/treatment in lymphoma (non-hodgkin's).
Begelomab Begelomab is a murine monoclonal antibody against CD26.
Belantamab mafodotin An anti B-cell maturation antigen antibody conjugated to a microtubule inhibitor to treat relapsed or refractory multiple myeloma.
Belatacept A selective T-cell costimulation blocker used in the prophylaxis of organ rejection in adult patients receiving a kidney transplant.
Belimumab A B-lymphocyte stimulator (BLyS)-specific inhibitor used to treat systemic lupus erythematosus and active lupus nephritis as an add-on therapy.
Beludavimab Beludavimab is under investigation in clinical trial NCT04746183 (AGILE (Early Phase Platform Trial for COVID-19)).
Bemarituzumab Bemarituzumab is under investigation in clinical trial NCT03694522 (A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (Mfolfox6) in Gastric/gastroesophageal Junction Cancer (FIGHT)).
Benralizumab A monoclonal antibody used to treat severe eosinophilic asthma.
Bentracimab Bentracimab is under investigation in clinical trial NCT04286438 (Bentracimab (PB2452) in Ticagrelor-treated Patients With Uncontrolled Major or Life-threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure).
Bermekimab Bermekimab is under investigation in clinical trial NCT01384630 (Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis).
Besilesomab A monoclonal antibody bound to technetium-99 used to find infection and inflammation in patients with suspected osteomyelitis.
Bevacizumab A monoclonal anti-VEGF-A antibody used intravenously with antineoplastic agents to treat many cancers, and intravitreally to treat neovascular (wet) age-related macular degeneration.
Bevacizumab zirconium Zr-89 Bevacizumab zirconium Zr-89 is under investigation in clinical trial NCT01338090 (89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors).
Bexmarilimab Bexmarilimab is under investigation in clinical trial NCT03733990 (A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients).
Bezlotoxumab A monoclonal antibody used to reduce the recurrence of Clostridium difficile infections.
Bhq-880 Not Annotated
BI-836826 Not Annotated
BI-836858 Not Annotated
BIIB015 Investigated for use/treatment in solid tumors.
Bimagrumab Bimagrumab has been used in trials studying the treatment and supportive care of Sarcopenia, Skeletal Muscle, Mechanical Ventilation, Sporadic Inclusion Body Myositis, and Sporadic Inclusion Body Myositis (sIBM), among others.
Bimekizumab An anti-IL-17A, IL-17F, and IL-17AF monoclonal antibody used in the treatment plaque psoriasis.
Birtamimab Birtamimab is under investigation in clinical trial NCT02312206 (The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis).
Bivatuzumab Investigated for use/treatment in cancer/tumors (unspecified) and head and neck cancer.
Bivatuzumab mertansine Not Annotated
Bleselumab Bleselumab is under investigation in clinical trial NCT02921789 (Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant...
Blinatumomab An antineoplastic antibody used to treat CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in relapsed and refractory patients, as well as those in first or second complete remission with minimal residual disease (MRD).
Blosozumab Blosozumab has been used in trials studying the basic science and treatment of Osteoporosis and Osteoporosis, Postmenopausal.
Bococizumab Bococizumab has been used in trials studying the treatment and prevention of Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, and Heterozygous Familial Hypercholesterolemia.
Brentuximab vedotin A CD30-directed antibody-drug conjugate used to treat various types of lymphoma.
Briakinumab Investigated for use/treatment in autoimmune diseases, crohn's disease, multiple sclerosis, psoriasis and psoriatic disorders, and rheumatoid arthritis.
Brodalumab A monoclonal antibody used to treat moderate to severe plaque psoriasis.
Brolucizumab An anti VEGF-A monoclonal antibody indicated to treat neovascular age related macular degeneration.
Brontictuzumab Brontictuzumab has been used in trials studying the treatment of Adenoid Cystic Carcinoma, Relapsed or Refractory Solid Tumors, and Relapsed or Refractory Lymphoid Malignancies.
Budigalimab Budigalimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 Is Administered in Combination With IV...
Burosumab A fibroblast growth factor 23 blocking antibody used to treat X-linked hypophosphatemia.
Cabiralizumab Cabiralizumab is under investigation in clinical trial NCT03502330 (APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma).
Calpurbatug Calpurbatug (TRL1068) is a high-affinity and broad-spectrum human antibody that targets and disintegrates bacterial biofilm.
Camrelizumab Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
Canakinumab An interleukin-1β blocker used to treat Periodic Fever Syndromes such as Cryopyrin-Associated Periodic Syndromes (CAPS) and Familial Mediterranean Fever (FMF), and also to treat active Systemic Juvenile Idiopathic Arthritis (SJIA).
Cantuzumab mertansine Not Annotated
Cantuzumab ravtansine Investigated for use/treatment in gastric cancer.
Caplacizumab A von Willebrand factor (vWF)-directed antibody fragment used to treat acquired thrombotic thrombocytopenic purpura (aTTP).
Capromab pendetide A monoclonal anti-prostate specific membrane antigen antibody used in imaging kits to target radioactive agents to malignant prostate tissue.
Carlumab Carlumab has been used in trials studying the treatment of Cancer and Prostate Cancer.
Carotuximab Investigated for use/treatment in solid tumors.
Casirivimab Part of an investigational recombinant monoclonal antibody cocktail used to treat mild to moderate COVID-19.
Catumaxomab For use in the management of malignant ascites tumours via intraperitoneal infusion where standard therapy is not available or feasible [FDA Label].
Cemiplimab A programmed death receptor-1 blocking antibody used to treat cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer.
Cendakimab Cendakimab is a recombinant humanized anti-interleukin 13 (IL-13) monoclonal antibody.
Cergutuzumab amunaleukin Cergutuzumab amunaleukin is under investigation in clinical trial NCT02004106 (A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors).
Certolizumab pegol A tumor necrosis factor (TNF) blocker used to treat a variety of autoimmune and autoinflammatory conditions like Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and plaque psoriasis.
Cetuximab An endothelial growth factor receptor binding fragment used to treat colorectal cancer as well as squamous cell carcinoma of the head and neck.
Cibisatamab Not Annotated
Cilgavimab An extended half-life recombinant monoclonal IgG1κ antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization.
Cixutumumab Cixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia, Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate. Cixutumumab is a highly specific recombinant...
Clazakizumab Clazakizumab has been used in trials studying the treatment of Rheumatoid Arthritis.
Clenoliximab Investigated for use/treatment in rheumatoid arthritis.
Clesrovimab An RSV fusion protein-directed monoclonal antibody that provides passive immunity against RSV infection in infants.
Clivatuzumab tetraxetan Not Annotated
CMB-401 Not Annotated
Codrituzumab Codrituzumab is under investigation in clinical trial NCT01507168 (A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma).
Coltuximab ravtansine Investigated for use/treatment in lymphoma (non-hodgkin's).
Conatumumab Conatumumab has been used in trials studying the treatment of Sarcoma, Lymphoma, Oncology, Colon Cancer, and Rectal Cancer, among others.
Concizumab A monoclonal antibody targeting tissue factor pathway inhibitor (TFPI) for the prophylaxis of bleeding episodes in patients with hemophilia A or B.
Cosibelimab A programmed death ligand-1 (PD-L1) blocking antibody used to treat metastatic or locally advanced cutaneous squamous cell carcinoma in selected adult patients.
CR002 Investigated for use/treatment in nephropathy.
Crenezumab Crenezumab has been used in trials studying the treatment of Alzheimer's Disease.
Crizanlizumab A monoclonal antibody that targets selectin to reduce the frequency of vasooclusive crises in patients with sickle cell disease.
Crotedumab Crotedumab has been used in trials studying the treatment of Diabetes Mellitus, Type 2.
Crovalimab A complement C5 inhibiting antibody used to treat paroxysmal nocturnal hemoglobinuria in adults and adolescents.
CT-011 Investigated for use/treatment in cancer/tumors (unspecified).
Cusatuzumab A CD70-directed monoclonal antibody under investigation for the treatment of hematological malignancies.
Dacetuzumab Investigated for use/treatment in lymphoma (non-hodgkin's) and multiple myeloma.
Daclizumab A monoclonal anti-CD25 antibody that blocks the interleukin-2 receptor which is used to treat relapsing forms of multiple sclerosis.
Dalantercept Dalantercept is under investigation in clinical trial NCT00996957 (Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma).
Dalotuzumab Dalotuzumab has been investigated for the treatment of Breast Cancer, Non Small Cell Lung Cancer, and Metastatic Colorectal Cancer.
Danburstotug Danburstotug is under investigation in clinical trial NCT04809012 (Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors).
Dapirolizumab pegol Dapirolizumab pegol is under investigation in clinical trial NCT02804763 (A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus).
Daratumumab A CD38-directed cytolytic antibody used alone or as an adjunct drug in the treatment of multiple myeloma and light chain amyloidosis.
Datopotamab deruxtecan An antibody-drug conjugate carrying a topoisomerase-I inhibitor payload for use in patients with previously treated HR+, HER2- breast cancer and EGFR+ non-small cell lung cancer.
DCLL-9718S DCLL9718S is an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1). DCLL9718S is under investigation in clinical trial NCT03298516 (A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid...
Demcizumab Demcizumab is under investigation for the treatment of Nonsquamous Nonsmall Cell Neoplasm of Lung.
Denosumab A RANK ligand (RANKL) inhibitor used for the management of osteoporosis in patients at high risk for bone fractures.
Depatuxizumab Depatuxizumab has been used in trials studying the treatment and diagnostic of Adenocarcinoma and Advanced Solid Tumors.
Depatuxizumab mafodotin No approved indication.
Depemokimab A interleukin-5-targeting monoclonal antibody used as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adults and children.
Dezamizumab Dezamizumab is under investigation in clinical trial NCT03417830 (Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging).
Digoxin Immune Fab (Ovine) An antibody binding fragment which binds digoxin molecules which is used as an antidote to digoxin overdose.
Dilpacimab Dilpacimab is under investigation in clinical trial NCT03368859 (A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and...
Dinutuximab An immunotherapeutic agent used in combination with other immunomodulating agents to treat high-risk neuroblastoma in pediatric patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
Disitamab vedotin Disitamab vedotin is an antibody-drug conjugate drug targeting human epidermal growth factor receptor 2 (HER2). It is currently being investigated for cancers.
Divozilimab Divozilimab is under investigation in clinical trial NCT05730699 (Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE)).
Domagrozumab Domagrozumab is under investigation in clinical trial NCT01616277 (A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects).
Donanemab An amyloid beta-directed antibody used to treat Alzheimer’s disease.
Dostarlimab An anti-PD-1 monoclonal antibody used in the treatment of mismatch repair deficient endometrial cancers and solid tumours with no alternative treatment options.
Drozitumab Drozitumab is a human monoclonal antibody directed against tumor necrosis factor receptor superfamily member 10B (TNFRSF10B), a member of tumor necrosis factor related apoptosis-inducing ligand (TRAIL). It was developed by...
Dulaglutide A GLP-1 agonist used to manage type 2 diabetes mellitus.
Duligotuzumab Duligotuzumab has been used in trials studying the treatment of Neoplasms, Colorectal Cancer, Head and Neck Cancer, and Epithelial Tumors, Malignant.
Dupilumab A monoclonal antibody used to treat various inflammatory disorders, including atopic dermatitis, asthma, and nasal polyps accompanied by chronic rhinosinusitis in adolescents and adults.
Durvalumab An antineoplastic monoclonal antibody used to treat urothelial carcinoma and locally advanced, unresectable non-small cell lung cancer.
Dusigitumab Dusigitumab has been used in trials studying the treatment of Cancer, Advanced Solid Malignancies, Unresectable or Metastatic Hepatocellular Carcinoma (HCC), and Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer.
EB05 EB05, in combination with standard of care (SOC), is being investigated in clinical trial NCT04401475 to evaluate its safety and efficacy in adult hospitalized patients with COVID-19 and ARDS.
Ecromeximab Ecromeximab has been used in trials studying the treatment of Cutaneous Melanoma and Metastatic Melanoma.
Eculizumab A recombinant humanized monoclonal antibody used to reduce the risk of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
EDI-200 EDI-200 is a fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1.
Edobacomab Not Annotated
Edratide Edratide is under investigation in clinical trial NCT00203151 (A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus).
Edrecolomab Not Annotated
Efalizumab A monoclonal anti-CD11a antibody used to treat moderate to severe plaque psoriasis.
Eflapegrastim A form of recombinant human granulocyte colony stimulating factor used to induce the production of granulocytes and lower infection risk after myelosuppressive therapy.
Eftrenonacog alfa A recombinant Factor IX used to treat and prevent bleeding in hemophilia B.
Efungumab Efungumab is under investigation in clinical trial NCT00217815 (Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer).
Eldelumab Investigated for use/treatment in ulcerative colitis.
Elezanumab Elezanumab is under investigation in clinical trial NCT03737812 (A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis).
Elgemtumab Elgemtumab is under investigation in clinical trial NCT02167854 (Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer).
Elotuzumab An antineoplastic agent and SLAMF7-directed immunostimulatory antibody used for the treatment of refractory multiple myeloma in combination with other antineoplastic agents.
Elranatamab A bispecific antibody used to treat adults with relapsed or refractory multiple myeloma.
Eluvixtamab Not Annotated
Emactuzumab Emactuzumab is under investigation in clinical trial NCT01494688 (A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors).
Emapalumab An interferon gamma blocking antibody used to treat primary hemophagocytic lymphohistiocytosis.
Emibetuzumab Emibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others.
Emicizumab An antibody against Factor IXa and Factor X used to treat hemophilia A.
Enavatuzumab Not Annotated
Enfortumab vedotin An antibody-drug conjugate comprised of a fully human monoclonal antibody and microtubule-disrupting chemotherapeutic agent used in the treatment of advanced or metastatic urothelial cancer.
Enibarcimab Enibarcimab is under investigation in clinical trial NCT03989531 (Adrecizumab in Cardiogenic Shock).
Enlimomab Not Annotated
Enoblituzumab Enoblituzumab is under investigation in clinical trial NCT02982941 (Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors).
Enokizumab Investigated for use/treatment in asthma.
Enoticumab Not Annotated
Ensituximab Ensituximab has been used in trials studying the treatment of Pancreatic Cancer, Adult, Metastatic Colorectal Cancer, and Metastatic Pancreatic Cancer.
Envafolimab Not Annotated
Epcoritamab A bispecific CD20-directed CD3 T-cell engager used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults.
Epratuzumab Investigated for use/treatment in leukemia (lymphoid), lymphoma (non-hodgkin's), and systemic lupus erythematosus.
Eptinezumab A monoclonal antibody directed against CGRP infused every 3 months for the preventive treatment of migraine in adults.
Erenumab A calcitonin-gene related peptide antagonist used to prevent migraines.
Ersodetug Not Annotated
Ertumaxomab Ertumaxomab is under investigation in clinical trial NCT00522457 (Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy).
Etaracizumab Etaracizumab has been investigated for the treatment of Psoriasis, Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, and Stage III Renal Cell Cancer.
Etesevimab Etesevimab in combination with bamlanivimab is used to treat mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients, including neonates, with positive results of direct SARS-CoV-2 viral...
Etrolizumab A humanized IgG1κ anti-β7 integrin subunit monoclonal antibody under investigation for use in ulcerative colitis and Crohn's disease.
Evolocumab A PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor antibody used as an adjunct to LDL cholesterol reducing therapies, aiding in the prevention of cardiovascular events and cardiovascular revascularization procedures.
Evorpacept Evorpacept is under investigation in clinical trial NCT04755244 (A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)).
Fanolesomab An anti-SSEA-1 monoclonal antibody used for imaging of the appendix and to diagnose appendicitis.
Faricimab An IgG1-derived bispecific antibody against VEGF-A and Ang-2 for the treatment of age-related macular degeneration and diabetic macular edema.
Farletuzumab Investigated for use/treatment in ovarian cancer.
Farletuzumab ecteribulin Farletuzumab ecteribulin is under investigation in clinical trial NCT04300556 (A Study to Evaluate the Safety, Tolerability, and Efficacy of Morab-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha...
Fasinumab A monoclonal antibody targeting nerve growth factor which is under investigation for the treatment of chronic cancer and non-cancer pain.
Felvizumab Not Annotated
Felzartamab Felzartamab is under investigation in clinical trial NCT04145440 (Trial to Assess Safety and Efficacy of MOR202 in Anti-pla2r + Membranous Nephropathy (Amn)).
Fezakinumab Fezakinumab has been used in trials studying the treatment of Atopic Dermatitis and Rheumatoid Arthritis.
Fibronectin Fibronectin is under investigation in clinical trial NCT01812239 (Vaginal Progesterone in Twins With Short Cervix).
Ficlatuzumab Ficlatuzumab has been used in trials studying the treatment of Acute Myeloid Leukemia, Non-small Cell Lung Cancer, Mullerian Mixed Tumor of Ovary, Relapsed Acute Myeloid Leukemia, and Refractory Acute Myeloid...
Figitumumab Figitumumab has been used in trials studying the treatment of Sarcoma, Solid Tumor, Breast Cancer, Lung Neoplasms, and Advanced Cancer, among others.
Firategrast Firategrast has been used in trials studying the treatment of Multiple Sclerosis.
Fletikumab Fletikumab is under investigation in clinical trial NCT01038674 (Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis).
Flotetuzumab Flotetuzumab is under investigation in clinical trial NCT02152956 (Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS).
Fontolizumab Investigated for use/treatment in crohn's disease and psoriasis and psoriatic disorders.
Foralumab Foralumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab, an Oral Anti-cd3 Antibody, in Patients With NASH and T2DM).
Fremanezumab A humanized monoclonal antibody directed against human calcitonin-gene related peptide to prevent migraines.
Fresolimumab Fresolimumab has been used in trials studying the treatment of Primary Brain Tumors, Metastatic Breast Cancer, Diffuse Systemic Sclerosis, Pleural Malignant Mesothelioma, and Primary Focal Segmental Glomerulosclerosis.
Frovocimab Frovocimab is under investigation in clinical trial NCT01671085 (A Study of LY3015014 in Healthy Participants With High Cholesterol).
Fulranumab Fulranumab has been used in trials studying the treatment of Pain, Cystitis, Neuralgia, Joint Pain, and Arthralgia, among others.
Futuximab Futuximab is under investigation in clinical trial NCT01955473 (Japanese Phase 1 Trial of Sym004 in Solid Tumors).
Galcanezumab A calcitonin-gene related peptide antagonist used to prevent migraines and treat cluster headaches.
Galiximab Investigated for use/treatment in lymphoma (non-hodgkin's), psoriasis and psoriatic disorders, bone metastases, multiple myeloma, prostate cancer, and rheumatoid arthritis.
Gancotamab Gancotamab is under investigation in clinical trial NCT02213744 (MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients).
Ganitumab Ganitumab has been used in trials studying the treatment of Colon Cancer, Rectal Cancer, Breast Cancer, Breast Tumors, and Breast Neoplasms, among others.
Gantenerumab A fully human IgG1κ monoclonal antibody with specificity for amyloid-beta oligomers and fibrils under investigation for the treatment of Alzheimer's disease.
Garadacimab An activated factor XII-directed monoclonal antibody for the prophylaxis of hereditary angioedema attacks.
Garetosmab An intravenous fully human anti-activin A IgG4 monoclonal antibody indicated for fibrodysplasia ossificans progressiva in adults, neutralizing activin A to prevent activation of mutant ACVR1 and reduce heterotopic ossification.
Gedivumab Gedivumab is under investigation in clinical trial NCT01877785 (A Study of MHAA4549A to Assess Safety And Pharmacokinetics in Healthy Volunteers).
Gemtuzumab ozogamicin A monoclonal anti-CD33 antibody used to treat CD33-positive acute myeloid leukemia.
Gevokizumab Gevokizumab has been used in trials studying the treatment of Acne Vulgaris, Osteoarthritis, Behcet's Uveitis, Pyoderma Gangrenosum, and Behcet's Disease Uveitis, among others. Gevokizumab acts as a modulator of cytokine...
Gimsilumab Gimsilumab is under investigation in clinical trial NCT01357759 (Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects).
Girentuximab Investigated for use/treatment in gall bladder cancer and renal cell carcinoma.
Glembatumumab vedotin Investigated for use/treatment in melanoma.
Glenzocimab Not Annotated
Glofitamab A bispecific monoclonal antibody directed against CD20 and CD3 which is used for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
GMA-161 GMA-161 is under investigation in clinical trial NCT00244257 (Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)).
Golimumab A TNFα inhibitor used in the symptomatic treatment of various active inflammatory disorders, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.
Gontivimab Gontivimab is under investigation in clinical trial NCT03468829 (Efficacy and Safety of ALX-0171 in Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients Who Present With Respiratory Syncytial Virus (RSV) Infection).
Gosuranemab Gosuranemab is under investigation in clinical trial NCT02460094 (Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy).
Gremubamab Gremubamab is under investigation in clinical trial NCT02255760 (Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults).
Guselkumab A monoclonal antibody used to treat moderate to severe plaque psoriasis.
Hemopexin Not Annotated
Hepatitis B immune globulin An injection of immunoglobulin G (IgG) antibodies to prevent the development of chronic Hepatitis B infection.
Hepatitis C immune globulin (human) Not Annotated
Human cytomegalovirus immune globulin A solution of immune globulin G against cytomegalovirus used to prevent transmission of cytomegalovirus after organ transplants.
Human immunoglobulin G A purified form of human immunoglobulin G and other proteins used to treat immunodeficiency and a wide variety of autoimmune disorders.
Human Interleukin 8 Interleukin-8 is under investigation in clinical trial NCT05148234 (BMS-986253 in Myelodysplastic Syndromes).
Human Rho(D) immune globulin A solution of antibodies used to prevent isoimmunization of Rho(D) negative patients exposed to Rho(D) positive blood in pregnancy or transfusion.
Human vaccinia virus immune globulin A purified gamma globulin used to treat vaccinia infections where skin is compromised, or infections of the eyes, mouth, or other areas where vaccinia infections present a special hazard.
Human varicella-zoster immune globulin A solution of antibodies used for post exposure prophylaxis of varicella infections in high risk populations, as well as to reduce the severity of infections.
Ianalumab Ianalumab is under investigation in clinical trial NCT01930175 (Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris).
Ibalizumab A CD4-specific antibody used to treat HIV infections.
Ibritumomab tiuxetan A monoclonal anti-CD20 antibody used to treat B-cell non-Hodgkin's lymphoma via a conjugated radioactive isotope.
Ichorcumab Ichorcumab is under investigation in clinical trial NCT03251482 (A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery).
Icrucumab Icrucumab is under investigation in clinical trial NCT01111604 (A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer).
Idarucizumab An antibody that binds dabigatran for the reversal of anticoagulant effects of dabigatran.
IGN311 Intended for the treatment of various forms of cancer.
IMC-1C11 Investigated for use/treatment in cancer/tumors (unspecified).
Imc-3c5 Not Annotated
Imc-eb10 Not Annotated
Imciromab pentetate Not Annotated
Imdevimab Part of an investigational recombinant monoclonal antibody cocktail used to treat mild to moderate COVID-19.
Imgatuzumab Imgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With...
IMMU-114 IMMU-114 is antibody-drug conjugate consisting of humanized anti-HLA-DR IgG4 monoclonal antibody specific for alpha-chain linked to SN-38 via a CL2A linker.
Inclacumab Inclacumab has been used in trials studying the treatment and prevention of Myocardial Infarction, Peripheral Arterial Disease (PAD), and Coronary Heart Disease, Graft Occlusion, Vascular.
Indatuximab ravtansine Indatuximab ravtansine is under investigation in clinical trial NCT01001442 (Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma).
Indium In-111 satumomab pendetide For diagnosis of extrahepatic malignant cancers
Indusatumab vedotin Indusatumab vedotin has been used in trials studying the treatment of Pancreatic Adenocarcinoma, Adenocarcinoma of the Stomach, Recurrent Gastric Adenocarcinoma, Metastatic Gastric Adenocarcinoma, and Advanced Gastrointestinal Carcinoma, among others.
Inebilizumab A humanized anti-CD19 cytolytic monoclonal antibody for B-cell depletion in autoimmune conditions.
Infliximab A monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.
INH-A21 INH-A21 is a human staphylococcal immunoglobulin
Inolimomab Inolimomab is under investigation as an agent to treat steroid-resistant graft vs host disease. It has thus far offered similar efficacy to other monoclonal antibody options, though it may carry...
Inotuzumab ozogamicin An antibody-drug conjugate used to treat B-cell precursor acute lymphoblastic leukemia (ALL).
Intetumumab Intetumumab has been used in trials studying the treatment of Melanoma.
Ipafricept Ipafricept is under investigation in clinical trial NCT01608867 (A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors).
IPH 2101 Investigated for use/treatment in leukemia (myeloid) and multiple myeloma.
Ipilimumab A human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.
Iratumumab Investigated for use/treatment in lymphoma (unspecified).
Isatuximab A chimeric monoclonal antibody targeted against surface CD38 glycoproteins for the treatment of multiple myeloma in patients who have failed previous therapies.
Iscalimab Iscalimab is under investigation in clinical trial NCT03905525 (Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjögren's Syndrome).
Istiratumab Istiratumab is under investigation in clinical trial NCT02399137 (A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer).
Itepekimab Itepekimab is under investigation in clinical trial NCT03546907 (Proof-of-concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-il-33 Mab) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)).
Itolizumab Itolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).
Ivuxolimab Ivuxolimab is under investigation in clinical trial NCT02554812 (A Study of Avelumab in Combination With Other Cancer Immunotherapies in Advanced Malignancies (JAVELIN Medley)).
Ixekizumab A monoclonal antibody used to treat moderate to severe plaque psoriasis.
Keliximab Not Annotated
KRN-330 Anti-a33 fully-human monoclonal antibody is under investigation in clinical trial NCT00838578 (Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer).
Labetuzumab Labetuzumab is a humanized monoclonal antibody used to treat cancer.
Labetuzumab govitecan Labetuzumab govitecan has been used in trials studying the treatment of Colon Cancer, Rectal Cancer, and Metastatic Colorectal Cancer.
Lacnotuzumab Lacnotuzumab is under investigation in clinical trial NCT01643850 (MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)).
Ladiratuzumab vedotin Ladiratuzumab vedotin is under investigation in clinical trial NCT01969643 (A Safety Study of SGN-LIV1A in Breast Cancer Patients).
Lampalizumab Lampalizumab has been used in trials studying the treatment of Geographic Atrophy.
Lanadelumab A monoclonal antibody targeted against kallikrein which is used to treat attacks of hereditary angioedema.
Landogrozumab Landogrozumab has been used in trials studying the treatment of Advanced Cancer, Muscular Atrophy, and Pancreatic Cancer.
Lebrikizumab An IgG4 monoclonal antibody against IL-13 used to treat moderate-to-severe atopic dermatitis in adults and adolescents.
Lecanemab An amyloid beta-targeting antibody used to treat Alzheimer’s Disease in patients with mild cognitive impairment or mild dementia with a known amyloid beta pathology.
Lenercept Not Annotated
Lenzilumab Lenzilumab is under investigation in clinical trial NCT02546284 (Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)).
Lerdelimumab Investigated for use/treatment in glaucoma and cataracts.
Leronlimab A humanized monoclonal antibody being investigated
Levilimab Levilimab is under investigation in clinical trial NCT04227366 (Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis).
Lexatumumab Investigated for use/treatment in cancer/tumors (unspecified).
Lifastuzumab vedotin Lifastuzumab vedotin is under investigation in clinical trial NCT01363947 (Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer).
Ligelizumab An IgE-directed monoclonal antibody under investigation for the treatment of chronic spontaneous urticaria (CSU).
Lintuzumab Lintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia).
Linvoseltamab A bispecific human IgG4 monoclonal antibody used for the treatment of multiple myeloma.
Lirentelimab Lirentelimab is under investigation in clinical trial NCT04856891 (A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis).
Lirilumab Lirilumab has been used in trials studying the treatment of Leukemia, CANCER,NOS, Multiple Myeloma, Lymphocytic Leukemia, and Acute Myeloid Leukemia, among others.
LMB-100 LMB-100 is a is an antibody-toxin conjugate with an antimesothelin Fab linked to a 24-kilodalton portion of Pseudomonas exotoxin A with mutations that decrease immunogenicity.
Lmb-7 Not Annotated
Lokivetmab Not Annotated
Loncastuximab tesirine An antibody-drug conjugate used for the treatment of relapsed and refractory B-cell lymphomas.
Lorukafusp alfa Lorukafusp alfa is under investigation in clinical trial NCT01334515 (Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma).
Lorvotuzumab mertansine Lorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others.
Losatuxizumab vedotin Not Annotated
Lucatumumab Investigated for use/treatment in leukemia (lymphoid), multiple myeloma, and lymphoma (unspecified).
Lulizumab pegol Lulizumab pegol is under investigation in clinical trial NCT02843659 (Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome).
Lumiliximab Investigated for use/treatment in asthma and leukemia (lymphoid).
Lumretuzumab Lumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer.
Lutikizumab Lutikizumab is under investigation in clinical trial NCT02087904 (A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis).
Ly-2787106 Not Annotated
Lys-plasminogen Lys-plasminogen is a truncated form of natural human plasminogen.
Maftivimab Part of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells.
Magrolimab Magrolimab is under investigation in clinical trial NCT02953782 (Trial of Magrolimab (Hu5f9-g4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer).
Mapatumumab Mapatumumab is under investigation in clinical trial NCT00094848 (Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-hodgkin's Lymphoma (NHL)).
Margetuximab An Fc-engineered human/mouse chimeric IgG1κ anti-HER2 monoclonal antibody indicated for patients with HER2-positive metastatic breast cancer.
Marstacimab An antagonist of tissue factor pathway inhibitor used to prevent bleeding caused by hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors.
Matuzumab Investigated for use/treatment in cervical dysplasia/cancer, colorectal cancer, gastric cancer, and lung cancer.
Mavrilimumab Mavrilimumab has been investigated for the treatment of Rheumatoid Arthritis.
MDX-1097 MDX-1097 is a chimeric monoclonal antibody directed against the kappa myeloma antigen (KMA).
Mdx-1342 Not Annotated
MDX-210 Not Annotated
Medi-3617 Not Annotated
Medi-4212 Not Annotated
MEDI-547 MEDI-547 is an anti-EphA1 monoclonal antibody conjugated to mcMMAF
Melrilimab Melrilimab is under investigation in clinical trial NCT03207243 (Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma).
Meplazumab Meplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with COVID-19 pneumonia.
Mepolizumab A fully-humanized monoclonal IgG1 kappa anti-IL-5 antibody used in conjunction with other therapies to treat severe asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome.
Milatuzumab Milatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), GVHD (Acute or Chronic), Myelodysplastic Syndrome, and Chronic Lymphocytic Leukemia, among others.
Mirikizumab An anti-IL-23 monoclonal antibody used as a second-line therapy for moderate-to-severe active ulcerative colitis.
Mirvetuximab soravtansine A folate receptor alpha-directed antibody and microtubule inhibitor conjugate used to treat folate receptor alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Mitazalimab Mitazalimab is under investigation in clinical trial NCT02379741 (ADC-1013 First-in-Human Study).
MK-4721 Investigated for use/treatment in prostate cancer.
MM-111 MM-111 is a novel bispecific antibody fusion protein that co-targets the the epidermal growth factor family receptor tyrosine kinases, ERBB2 and ERBB3.
Mogamulizumab A monoclonal antibody used to treat relapsed or refractory mycosis fungoides or Sézary syndrome after attempting one other therapy.
Monalizumab Monalizumab has been used in trials studying the treatment of Gynecologic Cancer, Chronic Lymphocytic Leukemia, and Squamous Cell Carcinoma of the Oral Cavity.
Mosunetuzumab A humanized anti-CD20/CD3 bispecific antibody used to treat relapsed or refractory follicular lymphoma.
Motavizumab Investigated for use/treatment in viral infection and pediatric indications.
Moxetumomab pasudotox A CD22-specific antibody conjugated to a truncated exotoxin used to treat relapsed or refractory hairy cell leukemia in patients who have already been treated with a purine nucleoside analog and one other treatment.
Mupadolimab CPI-006 was investigated in clinical trials NCT03454451, NCT04464395, and NCT04734873 to evaluate its safety and efficacy. NCT03454451 focused on advanced cancers (e.g., non-small cell lung cancer, renal cell cancer, colorectal...
Muromonab A monoclonal anti-CD3 antibody used as immunosuppressive therapy in kidney, heart, and liver transplant patients.
Namilumab Namilumab has been used in trials studying the treatment of Plaque Psoriasis and Rheumatoid Arthritis.
Naptumomab estafenatox Naptumomab Estafenatox has been used in trials studying the treatment of Pancreatic Cancer, Renal Cell Carcinoma, and Non-Small-Cell Lung Carcinoma.
Naratuximab emtansine Naratuximab emtansine is under investigation in clinical trial NCT01534715 (IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia).
Narsoplimab A human monoclonal antibody that binds to mannan-binding lectin-associated serine protease-2 (MASP-2) in the lectin pathway of the complement system, used in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy.
Natalizumab A monoclonal anti-integrin antibody used to treat Crohn's disease or multiple sclerosis.
NAV 1800 Investigated for use/treatment in colorectal cancer and solid tumors.
Navicixizumab Navicixizumab is under investigation in clinical trial NCT02298387 (A Phase 1 Study of Navicixizumab in Subjects With Solid Tumors).
Naxitamab A GD2-targeted IgG1 monoclonal antibody for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow.
Nebacumab Not Annotated
Necitumumab A monoclonal antibody used to treat metastatic squamous non-small cell lung cancer.
Nedosiran An antisense oligonucleotide used to treat primary hyperoxaluria type 1 in adults and high oxalate levels in children
Nemolizumab An interleukin-31 receptor alpha antagonist used to treat prurigo nodularis in adults.
Netakimab Netakimab is under investigation in clinical trial NCT03447704 (International Multicenter Comparative Randomized Placebo-controlled Clinical Study of Efficacy and Safety of BCD-085 in Patients With Ankylosing Spondylitis).
Nimotuzumab An EGFR-targeting monoclonal antibody used in the treatment of squamous cell carcinomas of the head and neck and glioblastomas.
Nipocalimab An intravenous aglycosylated human IgG1 anti-FcRn monoclonal antibody indicated for generalized myasthenia gravis and warm autoimmune hemolytic anemia, lowering circulating IgG and pathogenic autoantibodies by blocking FcRn-mediated IgG recycling.
Nirsevimab A long-acting monoclonal antibody indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants.
Nisevokitug Nisevokitug is a monoclonal antibody targeted against transforming growth factor beta (TGFβ) under investigation in NCT04097821 (A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel...
Nivolumab A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.
NKTT-120 NKTT-120 is a recombinant humanized IgG1k monoclonal antibody to human invariant T cell receptor (iTCR).
Nofazinlimab Nofazinlimab is under investigation in clinical trial NCT04194775 (A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma).
Obiltoxaximab A monoclonal antibody used for prophylaxis or treatment of inhalational anthrax.
Obinutuzumab An anti-CD20 antibody used to treat chronic lymphocytic leukemia, follicular lymphoma, and lupus nephritis.
Ocaratuzumab Ocaratuzumab is a humanized monoclonal antibody directed against CD20. It is being investigated for cancers and autoimmune disorders.
Ocrelizumab A CD20 specific monoclonal antibody used to treat relapsing remitting multiple sclerosis.
Odesivimab Part of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells.
Odulimomab Not Annotated
Ofatumumab An anti-CD20 antibody used for the treatment of chronic lymphocytic leukemia (CLL) in selected patients with certain treatment histories and responsiveness to anticancer medications.
Olaratumab A platelet-derived growth factor receptor alpha blocking antibody used with doxorubicin to treat patients with certain types of soft tissue sarcoma (STS).
Olendalizumab Olendalizumab is under investigation in clinical trial NCT01883544 (Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects).
Olinvacimab Olinvacimab is under investigation in clinical trial NCT03033524 (Trial to Evaluate the Safety of Ttac-0001(tanibirumab) in Recurrent Glioblastoma).
Olokizumab A humanized anti-IL-6 IgG4κ antibody under investigation for use in autoimmune conditions including rheumatoid arthritis.
Omalizumab A monoclonal anti-immunoglobulin E (IgE) antibody used to treat asthma, chronic idiopathic urticaria, chronic rhinosinusitis with nasal polyps, and IgE-mediated food allergy.
Omburtamab I-131 Not Annotated
Onartuzumab Onartuzumab has been used in trials studying the treatment of Neoplasms, Lung Cancer, Glioblastoma, Gastric Cancer, and Colorectal Cancer, among others.
ONCOLYSIN B Not Annotated
Ontamalimab Ontamalimab is under investigation in clinical trial NCT03627091 (Efficacy and Safety Study of SHP647 as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)).
Ontorpacept Not Annotated
Ontuxizumab Ontuxizumab is a humanized monoclonal antibody that targets endosialin or tumour endothelial marker 1 (TEM-1). It is under investigation in clinical trial NCT01574716 (Sarcoma Study of Morab-004 Utilization: Research and...
Opicinumab Opicinumab is under investigation in clinical trial NCT02641041 (Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants).
Oportuzumab monatox Investigated for use/treatment in bladder cancer and head and neck cancer.
Ordesekimab Ordesekimab is under investigation in clinical trial NCT02633020 (Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease).
Oregovomab Investigated for use/treatment in ovarian cancer.
Orilanolimab Orilanolimab is under investigation in clinical trial NCT03075878 (A Safety Study of SYNT001 in Subjects With Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA)).
Orticumab Orticumab is under investigation in clinical trial NCT04776629 (A Proof-of-activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors).
Osocimab Osocimab is under investigation in clinical trial NCT03276143 (Factor XIa inhibition for the prevention of venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty).
Otelixizumab Investigated for use/treatment in diabetes mellitus type 1, pediatric indications, and psoriasis and psoriatic disorders.
Otilimab Investigated for use/treatment in inflammatory disorders (unspecified).
Otlertuzumab Otlertuzumab is under investigation in clinical trial NCT01188681 (Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia).
Ozanezumab Ozanezumab has been used in trials studying the treatment of Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis, Relapsing-Remitting.
Ozoralizumab Ozoralizumab has been used in trials studying the treatment of Rheumatoid Arthritis and Active Rheumatoid Arthritis.
Pacibekitug Human anti-il-6 monoclonal antibody (pf-04236921) is under investigation in clinical trial NCT01405196 (Subcutaneous Treatment in Randomized Subjects to Evaluate Safety and Efficacy in Generalized Lupus Erythematosus).
Pagibaximab Not Annotated
Palivizumab A monoclonal anti respiratory syncytial virus F protein antibody used to prevent serious sequelae caused by respiratory syncytial virus infection in pediatric patients.
Pamrevlumab Pamrevlumab is under investigation in clinical trial NCT00913393 (Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy).
Panitumumab A recombinant humanized monoclonal antibody used to treat EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.
Parsatuzumab Parsatuzumab is under investigation in clinical trial NCT01366131 (Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous...
Pascolizumab Investigated for use/treatment in asthma.
Pateclizumab Pateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in...
Patritumab Patritumab has been used in trials studying the treatment of LUNG CANCER, Solid Tumors, Neoplasms by Site, Head and Neck Neoplasms, and Non-small Cell Lung Cancer, among others.
Patritumab deruxtecan Patritumab deruxtecan is under investigation in clinical trial NCT06596694 (Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)).
Pegdinetanib Investigated for use/treatment in cancer/tumors (unspecified) and macular degeneration.
Pembrolizumab A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.
Pemivibart A monoclonal antibody targeting SARS-CoV-2 spike protein used for pre-exposure prophylaxis against COVID-19 in certain immunocompromised patients.
Pemtumomab Pemtumomab is a murine monoclonal antibody radiolabeled with Yttrium-90. It targets the mucin 1 (MUC1) protein.
Penpulimab A monoclonal antibody immune checkpoint inhibitor targeted against programmed death receptor-1 (PD-1) used for the treatment of non-keratinizing nasopharyngeal carcinoma.
Pentaglobin Pentaglobin, also known as IgM-enriched immunoglobulin, falls under a group of polyclonal immunoglobulin preparations. It is comprised of immunoglobulin G (IgG) (https://www.drugbank.ca/drugs/DB00028) and immunoglobulin A (IgA) while also being enriched...
Pentigetide Pentigetide is a small molecule drug. The usage of the INN stem '-igetide' in the name indicates that Pentigetide is a peptide and glycopeptide. Pentigetide has a monoisotopic molecular weight...
Pepinemab Pepinemab is under investigation in clinical trial NCT03769155 (VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma).
Pertuzumab An antineoplastic agent used in the treatment of HER2-positive metastatic breast cancer in combination with other antineoplastic agents.
Pexelizumab For the treatment of inflammation during cardiac surgery.
PF-03475952 Not Annotated
Pf-03732010 Not Annotated
Pf-04605412 Not Annotated
Pidilizumab Pidilizumab is under investigation in clinical trial NCT01952769 (Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma).
Pinatuzumab vedotin Pinatuzumab vedotin is under investigation in clinical trial NCT01691898 (A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With...
Plasminogen Plasma-derived human plasminogen administered intravenously to treat type 1 plasminogen deficiency (hypoplasminogenemia).
Plozalizumab Plozalizumab has been investigated for the treatment of Atherosclerosis. Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found on the surface of certain white blood cells including...
Plutavimab Plutavimab is under investigation in clinical trial NCT04900428 (Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK)).
Polatuzumab vedotin A CD79b antibody conjugate indicated to treat different types of large B-cell lymphoma.
Ponezumab Ponezumab is under investigation in clinical trial NCT00607308 (A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease).
Pozelimab A human monoclonal IgG4 antibody used to treat CD55-deficient protein-losing enteropathy (PLE) or CHAPLE disease
PR-15 Investigated for use/treatment in atherosclerosis and thrombosis.
Prasinezumab Prasinezumab is under investigation in clinical trial NCT03100149 (A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease).
Priliximab Not Annotated
PRO-542 Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications.
Procizumab Procizumab is under investigation in clinical trial NCT06331884 (Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics/-Dynamics of AK1967 (Procizumab)).
Quilizumab Quilizumab is under investigation in clinical trial NCT01160861 (A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis).
Quisovalimab Not Annotated
Racotumomab Racotumomab has been used in trials studying the treatment of Glioma, Wilm's Tumor, Neuroblastoma, Retinoblastoma, and Ewing's Sarcoma.
Ralpancizumab Not Annotated
Ramucirumab An antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply.
Ranibizumab A recombinant humanized monoclonal antibody and VEGF-A antagonist used for the management of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.
Ravagalimab Ravagalimab is under investigation in clinical trial NCT03695185 (A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe It Is in Participants With Moderate to Severe Ulcerative Colitis...
Ravulizumab A monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis.
Raxibacumab A monoclonal antibody used in conjunction with an antibacterial regimen to treat patients with inhalational anthrax caused by Bacillus anthracis and for prophylaxis of inhalational anthrax when appropriate.
Refanezumab Refanezumab is under investigation in clinical trial NCT00833989 (Safety Escalating Repeat IV, in Stroke Patients).
Regavirumab Not Annotated
Regdanvimab A monoclonal antibody targeted against the SARS-CoV-2 spike protein used to treat patients with COVID-19 who are at risk of progressing to severe COVID-19.
Relatlimab A monoclonal antibody targeted against LAG-3 which is used in combination with nivolumab for the treatment of unresectable or metastatic melanoma.
Remtolumab Remtolumab is under investigation in clinical trial NCT02433340 (Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study).
Reslizumab An IL-5 antagonist used as an add-on maintenance treatment of patients with severe eosinophilic asthma in adults.
Respigam Not Available
Retifanlimab A PD-1–blocking antibody indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma.
Retlirafusp alfa Not Annotated
RI 624 Investigated for use/treatment in pain (acute or chronic).
Rilotumumab Rilotumumab has been investigated for the treatment of Cancer, Lung Cancer, Solid Tumors, Gastric Cancer, and Prostate Cancer, among others.
Risankizumab An interleukin-23 antagonist used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease in adults.
Rituximab A monoclonal anti-CD20 antibody used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris, and rheumatoid arthritis.
Robatumumab Robatumumab has been used in trials studying the treatment of Osteosarcoma, Sarcoma, Ewing's, and Peripheral Neuroectodermal Tumor.
Rocatinlimab Rocatinlimab is a subcutaneously administered anti-OX40 antibody developed for the treatment of moderate-to-severe atopic dermatitis. In clinical trials, it has shown significant efficacy and safety compared to a placebo. The...
Romlusevimab Romlusevimab (BRII-198) was under investigation in clinical trials (NCT04479644 and NCT04691180) to treat COVID-19, focusing on its safety, tolerability, and pharmacokinetics.
Romosozumab A monoclonal antibody used to treat osteoporosis in postmenopausal women at high risk of fracture, patients who are intolerant of other treatments, or patients who have failed other treatments.
Rontalizumab Rontalizumab has been used in trials studying the treatment of Systemic Lupus Erythematosus.
Rovalpituzumab tesirine Rovalpituzumab Tesirine has been used in trials studying the treatment of GLIOBLASTOMA, Malignant Melanoma, Other Solid Tumors, Small Cell Lung Cancer, and Medullary Thyroid Cancer, among others.
Rozanolixizumab A humanized monoclonal antibody targeting the human neonatal Fc receptor (FcRn) used to treat generalized myasthenia gravis.
Rozrolimupab Investigated for use/treatment in thrombocytopenia.
Ruplizumab Investigated for use/treatment in thrombocytopenia, systemic lupus erythematosus, transplant (rejection), blood (blood forming organ disorders, unspecified), and multiple sclerosis.
SAB-185 Not Available
Sabatolimab Sabatolimab is under investigation in clinical trial NCT03946670 (A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).).
Sacituzumab govitecan Sacituzumab govitecan targets TROP-2-expressing cancer cells through a humanized antibody (RS7) before subsequently becoming internalized and releasing the topoisomerase I inhibitor SN-38 to induce DNA damage-mediated apoptosis.
Samalizumab Samalizumab has been used in trials studying the treatment of Multiple Myeloma and B-cell Chronic Lymphocytic Leukemia.
Sar-566658 Not Annotated
Sarilumab A monoclonal antibody used to treat moderate to severe rheumatoid arthritis who have responded poorly or are intolerant of other DMARDs.
Satralizumab A subcutaneously injected anti-IL-6 receptor monoclonal antibody for the treatment of neuromyelitis optica spectrum disorder (NMOSD).
Secukinumab An immunomodulating agent and interleukin antagonist used to manage plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, along with other joint inflammatory disorders.
Selicrelumab Selicrelumab is under investigation in clinical trial NCT01008527 (Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100).
Semzuvolimab Semzuvolimab is under investigation in clinical trial NCT03149211 (To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults).
Senlizumab Not Annotated
Seribantumab Seribantumab has been used in trials studying the treatment of NSCLC, Heregulin, Adenocarcinoma, Colorectal Cancer, and Solid Tumor Cancers, among others.
Setrusumab Setrusumab is under investigation in clinical trial NCT01406548 (Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density).
Sevirumab Not Annotated
Sibeprenlimab A APRIL-directed monoclonal antibody used to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN).
Sibrotuzumab Investigated for use/treatment in cancer/tumors (unspecified), colorectal cancer, and lung cancer.
Sifalimumab Sifalimumab is a fully human monoclonal antibody targeting interferon-alpha. The levels of interferon-alpha are elevated in many patients with active systemic lupus erythematosus (SLE, or lupus) and other autoimmune disorders,...
Siltuximab An interleukin antagonist used to treat multicentric Castleman's disease (MCD) in patients who are HIV and HHV-8 negative.
Simtuzumab Simtuzumab has been used in trials studying the treatment and basic science of Myelofibrosis, Pancreatic Cancer, Colorectal Cancer, and Idiopathic Pulmonary Fibrosis.
Sintilimab Not Annotated
Sipavibart A monoclonal antibody used to prevent COVID-19 in immunocompromised patients.
Siplizumab Investigated for use/treatment in psoriasis and psoriatic disorders, transplant (rejection), graft versus host disease, lymphoma (unspecified), and leukemia (unspecified).
Sirukumab Sirukumab has been used in trials studying the treatment and basic science of Giant Cell Arteritis and Arthritis, Rheumatoid.
Sofituzumab vedotin Sofituzumab vedotin is under investigation in clinical trial NCT01335958 (Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer).
Solanezumab Solanezumab is under investigation for the treatment of Dementia, Alzheimers Disease, and Alzheimers Disease, Familial.
Solitomab Not Annotated
Sonelokimab Sonelokimab is under investigation in clinical trial NCT06411379 (Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa).
Sonepcizumab Investigated for use/treatment in solid tumors.
Sotatercept A recombinant activin receptor fusion protein used to treat pulmonary arterial hypertension.
Sotigalimab Sotigalimab is under investigation in clinical trial NCT03123783 (CD40 Agonistic Antibody APX005M in Combination With Nivolumab).
Sotrovimab A monoclonal antibody for the treatment of mild-to-moderate COVID-19 in patients at increased risk for death or hospitalization.
Spartalizumab Spartalizumab is under investigation in clinical trial NCT02605967 (Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma).
Spesolimab An interleukin-36 receptor antagonist used to treat generalized pustular psoriasis flares in adults.
Stamulumab Investigated for use/treatment in muscular dystrophy.
Sugemalimab An anti-PD-L1 monoclonal antibody used in combination with platinum-based chemotherapy for the treatment of metastatic non-small cell lung cancer.
Sulesomab Market product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes.
Sutimlimab A monoclonal antibody directed towards complement subunit C1s used to reduce the need for blood transfusion due to hemolysis in patients with cold agglutinin disease.
Suvratoxumab Suvratoxumab is under investigation in clinical trial NCT02296320 (Study of the Efficacy and Safety of MEDI4893).
Tabalumab Tabalumab has been used in trials studying the treatment of Autoimmune Disease, Rheumatoid Arthritis, Kidney Failure, Chronic, Connective Tissue Disease, and Systemic Lupus Erythematosus, among others.
Tafasitamab A CD19-directed cytolytic monoclonal antibody used in the treatment of B-cell malignancies.
Talacotuzumab Talacotuzumab is an IgG1 monoclonal antibody directed toward the IL3 receptor α–subunit, also known as CD123. It is under investigation in clinical trial NCT01632852 (A Study of CSL362 in Patients...
Talizumab Investigated for use/treatment in allergic reaction.
Talquetamab A bispecific antibody used to treat adults with relapsed or refractory multiple myeloma.
Tanezumab Tanezumab has been investigated for the treatment of Osteoarthritis, Knee and Neuralgia, Postherpetic.
Tarextumab Tarextumab has been used in trials studying the treatment of Solid Tumors, Stage IV Pancreatic Cancer, and Stage IV Small Cell Lung Cancer.
Tarlatamab A bispecific monoclonal antibody and T-cell engager targeting delta-like ligand 3 (DLL3) and CD3 to treat extensive-stage small cell lung cancer.
TB-402 Investigated for use/treatment in atrial fibrillation and thrombosis.
Tb-403 Not Annotated
Technetium Tc-99m arcitumomab For imaging colorectal tumors
Technetium Tc-99m nofetumomab merpentan Tc-99m nm is one of the technetium-labeled antibodies and it is indicated for the detection of small-cell lung cancer. The small cell lung cancer is a syndrome characterized by the...
Teclistamab A bispecific B-cell maturation antigen (BCMA)-directed CD3 T cell engager used to treat relapsed and refractory multiple myeloma in adults as monotherapy.
Tefibazumab Tefibazumab is under investigation in clinical trial NCT00198289 (Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs).
Telisotuzumab Telisotuzumab is under investigation in clinical trial NCT01472016 (Study of ABT-700 in Subjects With Advanced Solid Tumors).
Telisotuzumab vedotin An chemotherapeutic antibody-drug conjugate comprising a c-Met-directed antibody with a microtubule-disrupting small molecule payload.
Temelimab Temelimab is under investigation in clinical trial NCT02782858 (Clinical Trial Assessing the HERV-W Env Antagonist Gnbac1 for Efficacy in MS).
Teplizumab A CD3-directed monoclonal antibody indicated to delay the onset of Stage 3 type 1 diabetes in patients with Stage 2 type 1 diabetes.
Teprotumumab A fully human monoclonal antibody directed against insulin-like growth factor-1 receptor for the treatment of thyroid eye disease.
Tesidolumab Tesidolumab has been used in trials studying the treatment of Geographic Atrophy, Non-infectious Panuveitis, Exudative Macular Degeneration, Non-infectious Posterior Uveitis, and Age-related Macular Degeneration, among others.
Tetanus immune globulin, human A solution of antibodies used to prevent tetanus after an injury.
Tetulomab tetraxetan Lu-177 Betalutin has been used in trials studying the treatment of Non-Hodgkin Lymphoma and Relapsed, Diffuse Large B-cell Lymphoma.
Tezepelumab A human monoclonal IgG2λ thymic stromal lymphopoietin (TSLP)-blocking antibody for add-on maintenance therapy in severe asthma.
Theralizumab Theralizumab is a humanized anti-CD28 monoclonal antibody designed for treating autoimmune diseases and cancer. After the first human trial, it was withdrawn due to severe toxicity (likely due to lymphopenia...
Tibulizumab Tibulizumab is under investigation in clinical trial NCT03736772 (A Study of LY3090106 in Japanese and Caucasian Healthy Participants).
Tigatuzumab Tigatuzumab is under investigation in clinical trial NCT00991796 (CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)).
Tilavonemab Not Annotated
Tildrakizumab An interleukin-23 antagonist used to treat moderate to severe plaque psoriasis.
Timolumab Timolumab is a recombinant, fully-human, IgG4 immunoglobulin with antigen-binding specificity for human vascular adhesion protein-1 (VAP-1).
Tiragolumab Tiragolumab is under investigation in clinical trial NCT04513925 (A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)).
Tislelizumab An IgG4 variant monoclonal antibody against PD-1 indicated for the treatment of esophageal squamous cell carcinoma and various lung cancers
Tisotumab vedotin A tissue factor-directed antibody drug conjugate that is used to treat adults with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Tixagevimab An extended half-life recombinant monoclonal IgG1κ antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization.
TJ003234 Not Available
Tocilizumab An interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA).
TOL-101 Not Annotated
Tomaralimab Tomaralimab is under investigation in clinical trial NCT01794663 (Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function).
Tomuzotuximab Tomuzotuximab is under investigation in clinical trial NCT02052960 (CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer).
Toralizumab Toralizumab is under investigation in clinical trial NCT03605927 (CD40-L Blockade for Prevention of Acute Graft-versus-host Disease).
Toripalimab A PD-1 blocking monoclonal antibody used for the treatment of metastatic and recurrent nasopharyngeal carcinomas.
Tositumomab A monoclonal anti-CD20 antibody used to treat B-cell non-Hodgkin's lymphoma via a conjugated radioactive isotope.
Tositumomab I-131 Not Annotated
Tovetumab Tovetumab has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Advanced Solid Malignancies.
Tralokinumab A monoclonal antibody directed against interleukin-13 which is used in the treatment of moderate-to-severe atopic dermatitis in patients requiring systemic therapy.
Trastuzumab A monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast, gastroesophageal, and gastric cancers.
Trastuzumab deruxtecan An antibody used to treat certain types of unresectable or metastatic HER2 positive breast cancer.
Trastuzumab duocarmazine Trastuzumab duocarmazine is under investigation in clinical trial NCT03262935 (SYD985 vs. Physician's Choice in Participants With Her2-positive Locally Advanced or Metastatic Breast Cancer).
Trastuzumab emtansine An antineoplastic agent and antibody-drug conjugate used to treat HER2-overexpressing breast cancer.
Tregalizumab Tregalizumab has been used in trials studying the treatment of Rheumatoid Arthritis.
Tremelimumab An anti-CTLA-4 antibody used to treat unresectable hepatocellular carcinoma in combination with durvalumab.
Troplasminogen alfa Troplasminogen alfa is under investigation in clinical trial NCT00144014 (Safety and Efficacy Study in Acute Ischaemic Stroke).
Tucotuzumab celmoleukin Tucotuzumab celmoleukin is under investigation in clinical trial NCT00016237 (Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous...
Tusamitamab ravtansine Tusamitamab ravtansine is an antibody-drug conjugate that targets carcinoembryonic antigen-related cell adhesion molecule-5 (CEACAM5).
Ublituximab A low-fucose CD20-targeted monoclonal antibody used in the treatment of relapsing forms of multiple sclerosis.
Ulocuplumab Ulocuplumab is under investigation in Solid Tumor.
Upanovimab Upanovimab (SCTA01) was under investigation in clinical trials (NCT04683328, NCT04644185, NCT04709328 and NCT05156645) to evaluate its safety and efficacy in patients with severe COVID-19
Urelumab Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. Urelumab is a fully human antibody...
Urtoxazumab Not Annotated
Ustekinumab A targeted antibody therapy used to manage inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn's Disease, and ulcerative colitis.
Utomilumab Utomilumab is under investigation in clinical trial NCT03318900 (T Cell Immunotherapy for Advanced Ovarian Cancer).
Vadastuximab talirine Vadastuximab Talirine has been used in trials studying the treatment of Acute myeloid leukemia, Myelodysplastic Syndrome, Acute Myelogenous Leukemia, and Acute Promyelocytic Leukemia.
Valanafusp alfa Valanafusp alfa is under investigation in clinical trial NCT03071341 (Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I).
Vanucizumab Vanucizumab has been used in trials studying the treatment of ColoRectal Cancer and Advanced/Metastatic Solid Tumors.
Varlilumab Varlilumab has been used in trials studying the treatment of MELANOMA, Skin Ulcer, Burkett's Lymphoma, Mantle cell lymphoma, and Any T-cell Malignancy, among others.
Vatelizumab Vatelizumab has been used in trials studying the treatment of Ulcerative Colitis.
Vedolizumab An integrin blocker and anti-inflammatory agent used to manage ulcerative colitis and Crohn's disease in adults.
Veligrotug A humanized IgG1 monoclonal antibody and IGF-1R inhibitor indicated to treat proptosis and diplopia in thyroid eye disease regardless of activity or duration.
Veltuzumab Investigated for use/treatment in lymphoma (non-hodgkin's).
Vesencumab Vesencumab is under investigation in clinical trial NCT00747734 (A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors).
Vilobelimab An antibody directed against anti-human complement factor 5a is used to treat COVID-19 in adults for emergency use.
Visilizumab Visilizumab has been investigated for the treatment of Ulcerative Colitis.
Vobarilizumab Vobarilizumab is under investigation in clinical trial NCT02101073 (ALX-0061 Phase I Bioavailability Study in Healthy Volunteers).
Vofatamab Vofatamab is under investigation in clinical trial NCT02401542 (Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma).
Volagidemab Volagidemab is under investigation in clinical trial NCT03117998 (Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus).
Volociximab Investigated for use/treatment in solid tumors, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer.
Vonlerolizumab Vonlerolizumab is under investigation in clinical trial NCT03029832 (A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who...
Vopratelimab Vopratelimab is under investigation in clinical trial NCT02904226 (JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors).
Vorsetuzumab mafodotin Vorsetuzumab mafodotin is under investigation in clinical trial NCT01677390 (A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma).
Vunakizumab Vunakizumab is under investigation in clinical trial NCT03463187 (Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis).
XAV-19 XAV-19 is an intravenous antibody-based treatment targeted towards SARS-CoV-2 and other coronaviruses . The therapy concept is based on COVID-19 convalescent plasma. However, rather than using human plasma, XAV-19 is...
Xentuzumab Xentuzumab is under investigation in clinical trial NCT02191891 (Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)).
XmAb 2513 Investigated for use/treatment in lymphoma (unspecified) and lymphoma (non-hodgkin's).
XMMME-001-RTA Not Annotated
XomaZyme-791 Not Annotated
XTL-001 Investigated for use/treatment in hepatitis (viral, B).
Zalutumumab Zalutumumab is a fully human IgG1 monoclonal antibody designed to bind with selectivity to the epidermal growth factor receptor (EGFR). Zalutumumab has been investigated for the treatment of Squamous Cell...
Zanidatamab A bispecific HER2-targeted monoclonal antibody for HER2-positive biliary tract cancers.
Zanolimumab Zanolimumab is a fully human monoclonal antibody directed against CD4.
Zansecimab Zansecimab is under investigation in clinical trial NCT04342897 (A Study of LY3127804 in Participants With COVID-19).
Zenocutuzumab A HER2xHER3 bispecific antibody used to treat NRG1 gene fusion-positive cancers in adults.
Zilovertamab Not Annotated
Ziltivekimab Ziltivekimab is under investigation in clinical trial NCT06200207 (A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation).
Zimberelimab Not Annotated
Zolbetuximab A claudin-18.2-directed monoclonal antibody used in combination with platinum- and fluoropyrimidine-containing chemotherapy for advanced HER2 negative, CLDN18.2-positive gastric and GEJ cancers.
Zolimomab aritox Not Annotated
Drugs & Drug Targets: Drug Target Type
Abagovomab Mucin-16 target
Abatacept T-lymphocyte activation antigen CD80 target
Abatacept T-lymphocyte activation antigen CD86 target
Abciximab Vitronectin target
Abciximab Integrin alpha-IIb target
Abciximab Low affinity immunoglobulin gamma Fc region receptor II-b target
Abciximab Low affinity immunoglobulin gamma Fc region receptor II-a target
Abciximab Integrin beta-3 target
Abelacimab Coagulation factor XI target
Abituzumab Integrin alpha-V target
Abrilumab Integrin alpha-4 target
Abrilumab Integrin beta-7 target
Actoxumab Toxin A target
Adakitug Interleukin-8 target
Adalimumab Tumor necrosis factor target
Adecatumumab Epithelial cell adhesion molecule target
Aducanumab Amyloid-beta precursor protein target
Afelimomab Tumor necrosis factor target
AGS-16C3F Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 target
Alefacept T-cell surface antigen CD2 target
Alefacept Low affinity immunoglobulin gamma Fc region receptor III-B target
Alefacept Low affinity immunoglobulin gamma Fc region receptor III-A target
Alefacept Lymphocyte function-associated antigen 3 target
Alemtuzumab Low affinity immunoglobulin gamma Fc region receptor II-b target
Alemtuzumab Low affinity immunoglobulin gamma Fc region receptor II-a target
Alemtuzumab High affinity immunoglobulin gamma Fc receptor I target
Alemtuzumab Low affinity immunoglobulin gamma Fc region receptor III-A target
Alemtuzumab Low affinity immunoglobulin gamma Fc region receptor III-B target
Alemtuzumab CAMPATH-1 antigen target
Alemtuzumab Low affinity immunoglobulin gamma Fc region receptor II-c target
Alirocumab Proprotein convertase subtilisin/kexin type 9 target
Alpha-1-proteinase inhibitor Neutrophil elastase target
Amatuximab Mesothelin target
AMG 108 Interleukin-1 receptor type 1 target
AMG 108 Interleukin-1 receptor type 2 target
Amivantamab Epidermal growth factor receptor target
Amivantamab Hepatocyte growth factor receptor target
Amivantamab Low affinity immunoglobulin gamma Fc region receptor III-A target
Amubarvimab Spike glycoprotein target
Andecaliximab Matrix metalloproteinase-9 target
Anetumab ravtansine Mesothelin target
Anifrolumab Interferon alpha/beta receptor 1 target
Anifrolumab Interferon alpha/beta receptor 2 target
Anifrolumab Interferon gamma receptor 2 target
Anrukinzumab Interleukin-13 target
Ansuvimab Envelope glycoprotein target
Anthrax immune globulin human Protective antigen target
Anti-SARS-CoV-2 immunoglobulin Spike glycoprotein target
Anti-SARS-CoV-2 REGN-COV2 Spike glycoprotein target
Antithrombin III human Antithrombin-III target
Antithymocyte immunoglobulin (rabbit) T-cell surface glycoprotein CD1a target
Antithymocyte immunoglobulin (rabbit) Major histocompatibility complex class I-related protein 1 target
Antithymocyte immunoglobulin (rabbit) Integrin alpha-L target
Antithymocyte immunoglobulin (rabbit) T-lymphocyte activation antigen CD86 target
Antithymocyte immunoglobulin (rabbit) Low affinity immunoglobulin gamma Fc region receptor II-b target
Antithymocyte immunoglobulin (rabbit) T-cell surface glycoprotein CD4 target
Antithymocyte immunoglobulin (rabbit) Integrin beta-1 target
Antithymocyte immunoglobulin (rabbit) Integrin beta-3 target
Antithymocyte immunoglobulin (rabbit) Integrin alpha-V target
Anvatabart opadotin Receptor tyrosine-protein kinase erbB-2 target
Apitegromab Growth/differentiation factor 8 target
Apolizumab HLA-DR target
Apomab Tumor necrosis factor receptor superfamily member 10B target
Arcitumomab Cell adhesion molecule CEACAM3 target
Ascrinvacumab Activin receptor type-1-like target
Asfotase alfa Pyrophosphate target
ASI402 Mucin-1 target
Astegolimab Interleukin-1 receptor-like 1 target
Asunercept Tumor necrosis factor ligand superfamily member 6 target
Atezolizumab Programmed cell death 1 ligand 1 target
Atibuclimab Monocyte differentiation antigen CD14 target
Atoltivimab Envelope glycoprotein target
Av-203 Receptor tyrosine-protein kinase erbB-3 target
Avdoralimab C5a anaphylatoxin chemotactic receptor 1 target
AVE9633 Myeloid cell surface antigen CD33 target
AVE9633 Cytochrome P450 3A4 enzyme
Avelumab Programmed cell death 1 ligand 1 target
AVP-21D9 Protective antigen target
AVX-470 Tumor necrosis factor target
Axatilimab Macrophage colony-stimulating factor 1 receptor target
AZD7442 Spike glycoprotein target
Balstilimab Programmed cell death protein 1 target
Bamlanivimab Spike glycoprotein target
Bapineuzumab Amyloid-beta precursor protein target
Basiliximab Interleukin-2 receptor subunit beta target
Basiliximab Interleukin-2 receptor subunit alpha target
Batoclimab IgG receptor FcRn large subunit p51 target
Bavituximab Beta-2-glycoprotein 1 target
Bebtelovimab Spike glycoprotein target
Bectumomab B-cell receptor CD22 target
Begelomab Dipeptidyl peptidase 4 target
Belantamab mafodotin Solute carrier organic anion transporter family member 1B1 transporter
Belantamab mafodotin Solute carrier organic anion transporter family member 1B3 transporter
Belantamab mafodotin ATP-binding cassette sub-family C member 1 transporter
Belantamab mafodotin ATP-binding cassette sub-family C member 2 transporter
Belantamab mafodotin ATP-binding cassette sub-family C member 3 transporter
Belantamab mafodotin Bile salt export pump transporter
Belantamab mafodotin ATP-dependent translocase ABCB1 transporter
Belantamab mafodotin Tumor necrosis factor receptor superfamily member 17 target
Belatacept T-cell-specific surface glycoprotein CD28 target
Belatacept T-lymphocyte activation antigen CD80 target
Belatacept T-lymphocyte activation antigen CD86 target
Belimumab Tumor necrosis factor ligand superfamily member 13B target
Beludavimab Spike glycoprotein target
Bemarituzumab Fibroblast growth factor receptor 2 target
Bemarituzumab Low affinity immunoglobulin gamma Fc region receptor III-A target
Benralizumab Interleukin-5 target
Benralizumab Low affinity immunoglobulin gamma Fc region receptor III-A target
Benralizumab Interleukin-5 receptor subunit alpha target
Bermekimab Interleukin-1 alpha target
Besilesomab Carcinoembryonic antigen target
Bevacizumab Vascular endothelial growth factor A, long form target
Bevacizumab Complement C1q subcomponent subunit A target
Bevacizumab Complement C1q subcomponent subunit C target
Bevacizumab Low affinity immunoglobulin gamma Fc region receptor III-A target
Bevacizumab Low affinity immunoglobulin gamma Fc region receptor II-a target
Bevacizumab Low affinity immunoglobulin gamma Fc region receptor II-b target
Bevacizumab Low affinity immunoglobulin gamma Fc region receptor II-c target
Bevacizumab High affinity immunoglobulin gamma Fc receptor I target
Bevacizumab Complement C1q subcomponent subunit B target
Bevacizumab zirconium Zr-89 Vascular endothelial growth factor A, long form target
Bexmarilimab Stabilin-1 target
Bezlotoxumab Toxin B target
Bhq-880 Dickkopf-related protein 1 target
BI-836826 Leukocyte antigen CD37 target
BI-836858 Myeloid cell surface antigen CD33 target
BIIB015 Protein Cripto target
Bimagrumab Activin receptor type-2B target
Bimekizumab Interleukin-17F target
Bimekizumab Interleukin-17A target
Birtamimab Immunoglobulin kappa light chain target
Birtamimab Immunoglobulin lambda-1 light chain target
Bivatuzumab CD44 antigen target
Bleselumab Tumor necrosis factor receptor superfamily member 5 target
Blinatumomab T-cell surface glycoprotein CD3 delta chain target
Blinatumomab B-lymphocyte antigen CD19 target
Blosozumab Sclerostin target
Bococizumab Proprotein convertase subtilisin/kexin type 9 target
Brentuximab vedotin Tumor necrosis factor receptor superfamily member 8 target
Brentuximab vedotin Cytochrome P450 3A4 enzyme
Brentuximab vedotin ATP-binding cassette sub-family B member 5 transporter
Briakinumab Interleukin-12 subunit beta target
Briakinumab Interleukin-23 subunit alpha target
Brodalumab Interleukin-17A target
Brodalumab Interleukin-17 receptor E target
Brodalumab Interleukin-17 receptor D target
Brodalumab Interleukin-17 receptor C target
Brodalumab Interleukin-17 receptor B target
Brodalumab Interleukin-17 receptor A target
Brolucizumab Vascular endothelial growth factor A, long form target
Brontictuzumab Neurogenic locus notch homolog protein 1 target
Budigalimab Programmed cell death protein 1 target
Burosumab Fibroblast growth factor 23 target
Cabiralizumab Macrophage colony-stimulating factor 1 receptor target
Camrelizumab Programmed cell death protein 1 target
Canakinumab Interleukin-1 beta target
Cantuzumab mertansine Mucin-1 target
Cantuzumab ravtansine Mucin-1 target
Caplacizumab von Willebrand factor target
Capromab pendetide Prostate-specific antigen target
Capromab pendetide Glutamate carboxypeptidase 2 target
Carlumab C-C motif chemokine 2 target
Carotuximab Endoglin target
Casirivimab Spike glycoprotein target
Catumaxomab Epithelial cell adhesion molecule target
Catumaxomab Low affinity immunoglobulin gamma Fc region receptor II-a target
Catumaxomab Low affinity immunoglobulin gamma Fc region receptor III-A target
Catumaxomab Low affinity immunoglobulin gamma Fc region receptor III-B target
Catumaxomab T-cell surface glycoprotein CD3 epsilon chain target
Catumaxomab High affinity immunoglobulin gamma Fc receptor I target
Cemiplimab Programmed cell death protein 1 target
Cendakimab Interleukin-13 target
Cergutuzumab amunaleukin Interleukin-2 receptor target
Cergutuzumab amunaleukin Carcinoembryonic antigen target
Cergutuzumab amunaleukin Cell adhesion molecule CEACAM5 target
Certolizumab pegol Tumor necrosis factor target
Certolizumab pegol Aldo-keto reductase family 1 member A1 enzyme
Cetuximab Epidermal growth factor receptor target
Cetuximab Complement C1q subcomponent subunit A target
Cetuximab Low affinity immunoglobulin gamma Fc region receptor II-a target
Cetuximab High affinity immunoglobulin gamma Fc receptor I target
Cetuximab Low affinity immunoglobulin gamma Fc region receptor III-A target
Cetuximab Complement C1q subcomponent subunit C target
Cetuximab Complement C1q subcomponent subunit B target
Cetuximab Low affinity immunoglobulin gamma Fc region receptor III-B target
Cibisatamab T-cell surface glycoprotein CD3 epsilon chain target
Cibisatamab T-cell surface glycoprotein CD3 target
Cibisatamab Cell adhesion molecule CEACAM5 target
Cilgavimab Spike glycoprotein target
Cixutumumab Insulin-like growth factor 1 receptor target
Clazakizumab Interleukin-6 target
Clenoliximab T-cell surface glycoprotein CD4 target
Clesrovimab Fusion glycoprotein F0 target
Clivatuzumab tetraxetan Mucin-1 target
Codrituzumab Glypican-3 target
Coltuximab ravtansine B-lymphocyte antigen CD19 target
Coltuximab ravtansine Cytochrome P450 3A4 enzyme
Conatumumab Tumor necrosis factor receptor superfamily member 10B target
Concizumab Tissue factor pathway inhibitor target
Cosibelimab Programmed cell death 1 ligand 1 target
CR002 Platelet-derived growth factor D target
Crenezumab Amyloid-beta precursor protein target
Crizanlizumab P-selectin target
Crotedumab Glucagon receptor target
Crovalimab Complement C5 target
CT-011 Programmed cell death protein 1 target
Cusatuzumab CD70 antigen target
Dacetuzumab Tumor necrosis factor receptor superfamily member 5 target
Daclizumab Low affinity immunoglobulin gamma Fc region receptor II-b target
Daclizumab Interleukin-2 receptor subunit beta target
Daclizumab Low affinity immunoglobulin gamma Fc region receptor II-a target
Daclizumab High affinity immunoglobulin gamma Fc receptor I target
Daclizumab Low affinity immunoglobulin gamma Fc region receptor III-A target
Daclizumab Complement C1q subcomponent subunit C target
Daclizumab Complement C1q subcomponent subunit B target
Daclizumab Complement C1q subcomponent subunit A target
Daclizumab Complement C1r subcomponent target
Daclizumab Low affinity immunoglobulin gamma Fc region receptor II-c target
Daclizumab Interleukin-2 receptor subunit alpha target
Daclizumab Low affinity immunoglobulin gamma Fc region receptor III-B target
Dalantercept Growth/differentiation factor 2 target
Dalantercept Bone morphogenetic protein 10 target
Dalotuzumab Insulin-like growth factor 1 receptor target
Danburstotug Programmed cell death 1 ligand 1 target
Dapirolizumab pegol CD40 ligand target
Daratumumab ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 target
Datopotamab deruxtecan Solute carrier organic anion transporter family member 1B1 transporter
Datopotamab deruxtecan Tumor-associated calcium signal transducer 2 target
Datopotamab deruxtecan Solute carrier organic anion transporter family member 1B3 transporter
Datopotamab deruxtecan Multidrug and toxin extrusion protein 2 transporter
Datopotamab deruxtecan ATP-dependent translocase ABCB1 transporter
Datopotamab deruxtecan ATP-binding cassette sub-family C member 1 transporter
Datopotamab deruxtecan Broad substrate specificity ATP-binding cassette transporter ABCG2 transporter
Datopotamab deruxtecan DNA topoisomerase 1 target
DCLL-9718S C-type lectin domain family 12 member A target
Demcizumab Delta-like protein 4 target
Denosumab Tumor necrosis factor ligand superfamily member 11 target
Depatuxizumab Epidermal growth factor receptor target
Depatuxizumab mafodotin B-lymphocyte antigen CD19 target
Depatuxizumab mafodotin Tubulin beta chain target
Depatuxizumab mafodotin Epidermal growth factor receptor target
Depemokimab Interleukin-5 target
Dezamizumab Serum amyloid P-component target
Digoxin Immune Fab (Ovine) Digoxin target
Dilpacimab Vascular endothelial growth factor A, long form target
Dilpacimab Delta-like protein 4 target
Dinutuximab GD2 disialoganglioside target
Disitamab vedotin Receptor tyrosine-protein kinase erbB-2 target
Divozilimab B-lymphocyte antigen CD20 target
Domagrozumab Growth/differentiation factor 8 target
Donanemab Amyloid-beta precursor protein target
Donanemab Beta amyloid plaque target
Dostarlimab Programmed cell death protein 1 target
Drozitumab Tumor necrosis factor receptor superfamily member 10B target
Dulaglutide Glucagon-like peptide 1 receptor target
Duligotuzumab Epidermal growth factor receptor target
Duligotuzumab Receptor tyrosine-protein kinase erbB-3 target
Dupilumab Interleukin-4 receptor subunit alpha target
Dupilumab Interleukin-13 target
Dupilumab Interleukin-4 target
Durvalumab Programmed cell death 1 ligand 1 target
Dusigitumab Insulin-like growth factor 2 target
Dusigitumab Insulin-like growth factor 1 target
EB05 Toll-like receptor 4 target
Eculizumab Complement C5 target
EDI-200 Tumor necrosis factor receptor superfamily member EDAR target
Edrecolomab Epithelial cell adhesion molecule target
Efalizumab Integrin alpha-L target
Efalizumab Integrin alpha-X target
Eflapegrastim Granulocyte colony-stimulating factor receptor target
Eftrenonacog alfa Coagulation factor IX target
Eftrenonacog alfa IgG receptor FcRn large subunit p51 target
Eldelumab C-X-C motif chemokine 10 target
Elezanumab Repulsive guidance molecule A target
Elgemtumab Receptor tyrosine-protein kinase erbB-3 target
Elotuzumab SLAM family member 7 target
Elranatamab Tumor necrosis factor receptor superfamily member 17 target
Elranatamab T-cell surface glycoprotein CD3 target
Eluvixtamab T-cell surface glycoprotein CD3 target
Eluvixtamab T-cell surface glycoprotein CD3 epsilon chain target
Eluvixtamab Myeloid cell surface antigen CD33 target
Emactuzumab Macrophage colony-stimulating factor 1 receptor target
Emapalumab Interferon gamma target
Emibetuzumab Hepatocyte growth factor receptor target
Emicizumab Coagulation factor X target
Emicizumab Coagulation factor IX target
Enavatuzumab Tumor necrosis factor receptor superfamily member 12A target
Enfortumab vedotin ATP-dependent translocase ABCB1 transporter
Enfortumab vedotin Cytochrome P450 3A4 enzyme
Enfortumab vedotin Nectin-4 target
Enibarcimab Pro-adrenomedullin target
Enoblituzumab CD276 antigen target
Enokizumab Interleukin-9 target
Ensituximab Mucin-5AC target
Envafolimab Programmed cell death 1 ligand 1 target
Epcoritamab T-cell surface glycoprotein CD3 epsilon chain target
Epcoritamab B-lymphocyte antigen CD20 target
Epratuzumab B-cell receptor CD22 target
Eptinezumab Calcitonin gene-related peptides target
Eptinezumab Calcitonin gene-related peptide 2 target
Eptinezumab Calcitonin gene-related peptide 1 target
Erenumab Calcitonin gene-related peptide type 1 receptor target
Ersodetug Insulin receptor target
Ertumaxomab Receptor tyrosine-protein kinase erbB-2 target
Ertumaxomab T-cell surface glycoprotein CD3 epsilon chain target
Etaracizumab Integrin beta-3 target
Etaracizumab Integrin alpha-V target
Etesevimab Spike glycoprotein target
Etrolizumab Integrin beta-7 target
Evolocumab Proprotein convertase subtilisin/kexin type 9 target
Evorpacept Leukocyte surface antigen CD47 target
Faricimab Angiopoietin-2 target
Faricimab Vascular endothelial growth factor A, long form target
Farletuzumab Folate receptor alpha target
Farletuzumab ecteribulin Folate receptor alpha target
Fasinumab Beta-nerve growth factor target
Felzartamab ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 target
Fezakinumab Interleukin-22 target
Ficlatuzumab Hepatocyte growth factor target
Figitumumab Insulin-like growth factor 1 receptor target
Firategrast Integrin beta-7 target
Firategrast Integrin alpha-4 target
Firategrast VLA-4 (very late antigen-4) target
Fletikumab Interleukin-20 target
Flotetuzumab Interleukin-3 receptor subunit alpha target
Fontolizumab Interferon gamma target
Foralumab T-cell surface glycoprotein CD3 target
Foralumab T-cell surface glycoprotein CD3 epsilon chain target
Fremanezumab Calcitonin gene-related peptide 1 target
Fremanezumab Calcitonin gene-related peptide 2 target
Fremanezumab Calcitonin gene-related peptide type 1 receptor target
Fremanezumab Calcitonin gene-related peptides target
Fresolimumab Transforming growth factor beta-3 proprotein target
Fresolimumab Transforming growth factor beta-2 proprotein target
Fresolimumab Transforming growth factor beta-1 proprotein target
Frovocimab Proprotein convertase subtilisin/kexin type 9 target
Fulranumab Beta-nerve growth factor target
Futuximab Epidermal growth factor receptor target
Galcanezumab Calcitonin gene-related peptide 1 target
Galcanezumab Calcitonin gene-related peptide 2 target
Galcanezumab Calcitonin gene-related peptide type 1 receptor target
Galcanezumab Calcitonin gene-related peptides target
Galiximab T-lymphocyte activation antigen CD80 target
Gancotamab DNA topoisomerase 2-alpha target
Gancotamab Receptor tyrosine-protein kinase erbB-2 target
Ganitumab Insulin-like growth factor 1 receptor target
Gantenerumab Amyloid-beta precursor protein target
Garadacimab Coagulation factor XII target
Garetosmab Inhibin beta A chain target
Gemtuzumab ozogamicin Low affinity immunoglobulin gamma Fc region receptor III-A target
Gemtuzumab ozogamicin Low affinity immunoglobulin gamma Fc region receptor III-B target
Gemtuzumab ozogamicin Myeloid cell surface antigen CD33 target
Gemtuzumab ozogamicin High affinity immunoglobulin gamma Fc receptor I target
Gevokizumab Interleukin-1 beta target
Gimsilumab Granulocyte-macrophage colony-stimulating factor target
Girentuximab Interleukin-2 target
Girentuximab Carbonic anhydrase 9 target
Glembatumumab vedotin Transmembrane glycoprotein NMB target
Glenzocimab Platelet glycoprotein VI target
Glofitamab T-cell surface glycoprotein CD3 target
Glofitamab B-lymphocyte antigen CD20 target
GMA-161 Low affinity immunoglobulin gamma Fc region receptor III-A target
GMA-161 Low affinity immunoglobulin gamma Fc region receptor III-B target
Golimumab Tumor necrosis factor target
Gontivimab Fusion glycoprotein F0 target
Gosuranemab Microtubule-associated protein tau target
Gremubamab PcrV target
Guselkumab Interleukin-23 subunit alpha target
Hepatitis B immune globulin HBsAg target
Hepatitis C immune globulin (human) Genome polyprotein target
Human immunoglobulin G Complement C4-A target
Human immunoglobulin G Putative high affinity immunoglobulin gamma Fc receptor IB target
Human immunoglobulin G Low affinity immunoglobulin gamma Fc region receptor II-c target
Human immunoglobulin G Low affinity immunoglobulin gamma Fc region receptor II-b target
Human immunoglobulin G Low affinity immunoglobulin gamma Fc region receptor II-a target
Human immunoglobulin G Complement C3 target
Human immunoglobulin G High affinity immunoglobulin gamma Fc receptor I target
Human immunoglobulin G Complement C5 target
Human immunoglobulin G Complement C4-B target
Human immunoglobulin G Low affinity immunoglobulin gamma Fc region receptor III-A target
Human immunoglobulin G Low affinity immunoglobulin gamma Fc region receptor III-B target
Human Interleukin 8 Interleukin-8 target
Human Interleukin 8 C-X-C chemokine receptor type 2 target
Human Interleukin 8 C-X-C chemokine receptor type 4 target
Human Rho(D) immune globulin Rhesus blood group D antigen target
Ianalumab Tumor necrosis factor receptor superfamily member 13C target
Ibalizumab C-X-C chemokine receptor type 4 target
Ibalizumab C-C chemokine receptor type 5 target
Ibalizumab T-cell surface glycoprotein CD4 target
Ibritumomab tiuxetan B-lymphocyte antigen CD20 target
Ichorcumab Prothrombin target
Icrucumab Vascular endothelial growth factor receptor 1 target
IGN311 Epidermal growth factor receptor target
IGN311 Receptor tyrosine-protein kinase erbB-2 target
IMC-1C11 Vascular endothelial growth factor receptor 3 target
IMC-1C11 Vascular endothelial growth factor receptor 1 target
IMC-1C11 Vascular endothelial growth factor receptor 2 target
Imc-3c5 Vascular endothelial growth factor receptor 3 target
Imdevimab Spike glycoprotein target
Imgatuzumab Low affinity immunoglobulin gamma Fc region receptor III-A target
Imgatuzumab Epidermal growth factor receptor target
IMMU-114 HLA-DR target
Inclacumab P-selectin target
Indatuximab ravtansine Syndecan-1 target
Indium In-111 satumomab pendetide Tumor-associated glycoprotein 72 (TAG-72) target
Indusatumab vedotin Guanylyl cyclase C target
Inebilizumab B-lymphocyte antigen CD19 target
Infliximab Tumor necrosis factor target
Inolimomab Interleukin-2 receptor subunit alpha target
Inotuzumab ozogamicin B-cell receptor CD22 target
Inotuzumab ozogamicin ATP-dependent translocase ABCB1 transporter
Intetumumab Integrin alpha-V target
Ipafricept Frizzled-8 target
IPH 2101 Killer cell immunoglobulin-like receptor 2DL1 target
IPH 2101 Killer cell immunoglobulin-like receptor 2DL3 target
IPH 2101 Killer cell immunoglobulin-like receptor 2DL2 target
Ipilimumab Cytotoxic T-lymphocyte protein 4 target
Iratumumab Tumor necrosis factor receptor superfamily member 8 target
Isatuximab ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 target
Iscalimab Tumor necrosis factor receptor superfamily member 5 target
Istiratumab Receptor tyrosine-protein kinase erbB-3 target
Istiratumab Insulin-like growth factor 1 receptor target
Itepekimab Interleukin-33 target
Itolizumab T-cell differentiation antigen CD6 target
Ivuxolimab Tumor necrosis factor receptor superfamily member 4 target
Ixekizumab Interleukin-17A target
KRN-330 Cell surface A33 antigen target
Labetuzumab Cell adhesion molecule CEACAM5 target
Labetuzumab govitecan DNA topoisomerase 1 target
Labetuzumab govitecan Cell adhesion molecule CEACAM5 target
Lacnotuzumab Macrophage colony-stimulating factor 1 target
Ladiratuzumab vedotin Zinc transporter ZIP6 target
Lampalizumab Complement factor D target
Lanadelumab Plasma kallikrein target
Landogrozumab Growth/differentiation factor 8 target
Lebrikizumab Interleukin-13 target
Lecanemab Amyloid-beta precursor protein target
Lenzilumab Granulocyte-macrophage colony-stimulating factor target
Lerdelimumab Transforming growth factor beta-2 proprotein target
Leronlimab C-C chemokine receptor type 5 target
Levilimab Interleukin-6 receptor subunit alpha target
Lexatumumab Tumor necrosis factor receptor superfamily member 10B target
Lifastuzumab vedotin Sodium-dependent phosphate transport protein 2B target
Ligelizumab Immunoglobulin heavy constant epsilon target
Lintuzumab Myeloid cell surface antigen CD33 target
Linvoseltamab T-cell surface glycoprotein CD3 delta chain target
Linvoseltamab Tumor necrosis factor receptor superfamily member 17 target
Lirentelimab Sialic acid-binding Ig-like lectin 8 target
Lirilumab Killer cell immunoglobulin-like receptor 2DL3 target
Lirilumab Killer cell immunoglobulin-like receptor 2DL2 target
Lirilumab Killer cell immunoglobulin-like receptor 2DL1 target
LMB-100 Elongation factor 2 target
LMB-100 Mesothelin target
Loncastuximab tesirine B-lymphocyte antigen CD19 target
Loncastuximab tesirine Cytochrome P450 3A5 enzyme
Loncastuximab tesirine ATP-dependent translocase ABCB1 transporter
Loncastuximab tesirine Cytochrome P450 3A4 enzyme
Lorukafusp alfa GD2 disialoganglioside target
Lorvotuzumab mertansine Cytochrome P450 3A4 enzyme
Lorvotuzumab mertansine Neural cell adhesion molecule 1 target
Lucatumumab Tumor necrosis factor receptor superfamily member 5 target
Lulizumab pegol T-cell-specific surface glycoprotein CD28 target
Lumiliximab Low affinity immunoglobulin epsilon Fc receptor target
Lumretuzumab Receptor tyrosine-protein kinase erbB-3 target
Lutikizumab Interleukin-1 alpha target
Lutikizumab Interleukin-1 beta target
Maftivimab Envelope glycoprotein target
Magrolimab Leukocyte surface antigen CD47 target
Mapatumumab Tumor necrosis factor receptor superfamily member 10A target
Margetuximab Receptor tyrosine-protein kinase erbB-2 target
Marstacimab Tissue factor pathway inhibitor target
Matuzumab Epidermal growth factor receptor target
Mavrilimumab Granulocyte-macrophage colony-stimulating factor receptor subunit alpha target
MDX-1097 Immunoglobulin kappa light chain target
Mdx-1342 B-lymphocyte antigen CD19 target
MDX-210 High affinity immunoglobulin gamma Fc receptor I target
MDX-210 Receptor tyrosine-protein kinase erbB-2 target
Melrilimab Interleukin-1 receptor-like 1 target
Melrilimab Interleukin-33 target
Meplazumab Basigin target
Mepolizumab Interleukin-5 target
Milatuzumab HLA class II histocompatibility antigen gamma chain target
Mirikizumab Interleukin-12 subunit alpha target
Mirikizumab Interleukin-23 subunit alpha target
Mirvetuximab soravtansine Folate receptor alpha target
Mirvetuximab soravtansine Cytochrome P450 3A4 enzyme
Mirvetuximab soravtansine ATP-dependent translocase ABCB1 transporter
Mitazalimab Tumor necrosis factor receptor superfamily member 5 target
MK-4721 Prostate stem cell antigen target
MM-111 Receptor tyrosine-protein kinase erbB-3 target
MM-111 Receptor tyrosine-protein kinase erbB-2 target
Mogamulizumab C-C chemokine receptor type 4 target
Monalizumab NKG2-A/NKG2-B type II integral membrane protein target
Mosunetuzumab T-cell surface glycoprotein CD3 epsilon chain target
Mosunetuzumab B-lymphocyte antigen CD20 target
Motavizumab Fusion glycoprotein F0 target
Moxetumomab pasudotox B-cell receptor CD22 target
Moxetumomab pasudotox Elongation factor 2 target
Mupadolimab 5'-nucleotidase target
Muromonab T-cell surface glycoprotein CD3 gamma chain target
Muromonab T-cell surface glycoprotein CD3 delta chain target
Muromonab T-cell surface glycoprotein CD3 zeta chain target
Muromonab Low affinity immunoglobulin gamma Fc region receptor III-B target
Muromonab T-cell surface glycoprotein CD3 epsilon chain target
Namilumab Granulocyte-macrophage colony-stimulating factor target
Naptumomab estafenatox Trophoblast glycoprotein target
Naratuximab emtansine Leukocyte antigen CD37 target
Narsoplimab Mannan-binding lectin serine protease 2 target
Natalizumab Low affinity immunoglobulin gamma Fc region receptor III-B target
Natalizumab High affinity immunoglobulin gamma Fc receptor I target
Natalizumab Integrin alpha-4 target
Natalizumab Intercellular adhesion molecule 1 target
Navicixizumab Vascular endothelial growth factor A, long form target
Navicixizumab Delta-like protein 4 target
Naxitamab GD2 disialoganglioside target
Necitumumab Epidermal growth factor receptor target
Nedosiran L-lactate dehydrogenase A chain target
Nemolizumab Interleukin-31 receptor subunit alpha target
Netakimab Interleukin-17A target
Nimotuzumab Epidermal growth factor receptor target
Nipocalimab IgG receptor FcRn large subunit p51 target
Nirsevimab Fusion glycoprotein F0 target
Nirsevimab Fusion glycoprotein F0 target
Nirsevimab Fusion glycoprotein F0 target
Nisevokitug Transforming growth factor beta-1 proprotein target
Nivolumab Programmed cell death protein 1 target
NKTT-120 High affinity immunoglobulin gamma Fc receptor I target
NKTT-120 Low affinity immunoglobulin gamma Fc region receptor III-A target
Nofazinlimab Programmed cell death protein 1 target
Obiltoxaximab Protective antigen target
Obinutuzumab B-lymphocyte antigen CD20 target
Ocaratuzumab B-lymphocyte antigen CD20 target
Ocrelizumab B-lymphocyte antigen CD20 target
Odesivimab Envelope glycoprotein target
Ofatumumab B-lymphocyte antigen CD20 target
Olaratumab Platelet-derived growth factor receptor alpha target
Olendalizumab Complement C5 target
Olinvacimab Vascular endothelial growth factor receptor 2 target
Olokizumab Interleukin-6 target
Omalizumab High affinity immunoglobulin epsilon receptor subunit gamma target
Omalizumab Immunoglobulin heavy constant epsilon target
Omburtamab I-131 CD276 antigen target
Onartuzumab Hepatocyte growth factor receptor target
Ontamalimab Mucosal addressin cell adhesion molecule 1 target
Ontorpacept Leukocyte surface antigen CD47 target
Ontuxizumab Endosialin target
Opicinumab Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 target
Oportuzumab monatox Epithelial cell adhesion molecule target
Oportuzumab monatox Elongation factor 2 target
Ordesekimab Interleukin-15 target
Oregovomab Mucin-16 target
Orilanolimab IgG receptor FcRn large subunit p51 target
Orticumab Apolipoprotein B-100 target
Osocimab Coagulation factor XI target
Otelixizumab T-cell surface glycoprotein CD3 epsilon chain target
Otilimab Granulocyte-macrophage colony-stimulating factor target
Otlertuzumab Leukocyte antigen CD37 target
Ozanezumab Reticulon-4 target
Ozoralizumab Tumor necrosis factor target
Pacibekitug Interleukin-6 target
Palivizumab Fusion glycoprotein F0 target
Palivizumab Low affinity immunoglobulin gamma Fc region receptor III-B target
Palivizumab Complement C1r subcomponent target
Palivizumab Complement C1q subcomponent subunit A target
Palivizumab Complement C1q subcomponent subunit B target
Palivizumab Complement C1q subcomponent subunit C target
Palivizumab Low affinity immunoglobulin gamma Fc region receptor III-A target
Palivizumab High affinity immunoglobulin gamma Fc receptor I target
Palivizumab Low affinity immunoglobulin gamma Fc region receptor II-b target
Palivizumab Fusion glycoprotein F0 target
Pamrevlumab CCN family member 2 target
Panitumumab Epidermal growth factor receptor target
Parsatuzumab Epidermal growth factor-like protein 7 target
Pascolizumab Interleukin-4 target
Pateclizumab Lymphotoxin-alpha target
Patritumab Receptor tyrosine-protein kinase erbB-3 target
Patritumab deruxtecan DNA topoisomerase 1 target
Patritumab deruxtecan Receptor tyrosine-protein kinase erbB-3 target
Pegdinetanib Vascular endothelial growth factor receptor 2 target
Pembrolizumab Programmed cell death protein 1 target
Pembrolizumab Programmed cell death 1 ligand 1 target
Pemivibart Spike glycoprotein target
Pemtumomab Mucin-1 target
Penpulimab Programmed cell death protein 1 target
Pentaglobin Interleukin-2 target
Pepinemab Semaphorin-4D target
Pertuzumab Receptor tyrosine-protein kinase erbB-2 target
Pexelizumab Complement C5 target
Pf-03732010 Cadherin-3 target
Pf-04605412 Fibronectin receptor target
Pidilizumab Programmed cell death protein 1 target
Pinatuzumab vedotin B-cell receptor CD22 target
Plasminogen Fibrinogen target
Plasminogen Urokinase-type plasminogen activator enzyme
Plasminogen Tissue-type plasminogen activator enzyme
Plozalizumab C-C chemokine receptor type 2 target
Plutavimab Spike glycoprotein target
Polatuzumab vedotin Cytochrome P450 3A4 enzyme
Polatuzumab vedotin B-cell antigen receptor complex-associated protein beta chain target
Polatuzumab vedotin ATP-dependent translocase ABCB1 transporter
Polatuzumab vedotin Cytochrome P450 3A5 enzyme
Ponezumab Amyloid-beta precursor protein target
Pozelimab Complement C5 target
PR-15 Collagen alpha-1(III) chain target
PR-15 Collagen alpha-2(I) chain target
PR-15 Collagen alpha-1(I) chain target
Prasinezumab Alpha-synuclein target
Priliximab T-cell surface glycoprotein CD4 target
PRO-542 Free fatty acid receptor 4 target
Procizumab Dipeptidyl peptidase 3 target
Quilizumab Immunoglobulin heavy constant epsilon target
Quisovalimab Tumor necrosis factor ligand superfamily member 14 target
Ramucirumab Vascular endothelial growth factor receptor 2 target
Ranibizumab Vascular endothelial growth factor A, long form target
Ravagalimab CD40 ligand target
Ravulizumab Complement C5 target
Raxibacumab Protective antigen target
Refanezumab Myelin-associated glycoprotein target
Regdanvimab Spike glycoprotein target
Relatlimab Lymphocyte activation gene 3 protein target
Remtolumab Interleukin-17A target
Remtolumab Tumor necrosis factor target
Reslizumab Interleukin-5 target
Retifanlimab Programmed cell death protein 1 target
Retlirafusp alfa Transforming growth factor beta-3 proprotein target
Retlirafusp alfa Transforming growth factor beta-1 proprotein target
Retlirafusp alfa Programmed cell death 1 ligand 1 target
RI 624 Beta-nerve growth factor target
Rilotumumab Hepatocyte growth factor target
Risankizumab Interleukin-23 target
Risankizumab Interleukin-23 subunit alpha target
Rituximab B-lymphocyte antigen CD20 target
Robatumumab Insulin-like growth factor 1 receptor target
Rocatinlimab Tumor necrosis factor receptor superfamily member 4 target
Romlusevimab Spike glycoprotein target
Romosozumab Sclerostin target
Rontalizumab Interferon alpha-2 target
Rovalpituzumab tesirine Delta-like protein 3 target
Rozanolixizumab IgG receptor FcRn large subunit p51 target
Rozrolimupab Rhesus blood group D antigen target
Rozrolimupab Blood group Rh(D) polypeptide target
Ruplizumab CD40 ligand target
SAB-185 Spike glycoprotein target
Sabatolimab Hepatitis A virus cellular receptor 2 target
Sacituzumab govitecan Tumor-associated calcium signal transducer 2 target
Sacituzumab govitecan DNA topoisomerase 1 target
Sacituzumab govitecan Far upstream element-binding protein 1 target
Sacituzumab govitecan UDP-glucuronosyltransferase 1A1 enzyme
Samalizumab OX-2 membrane glycoprotein target
Sarilumab Interleukin-6 receptor subunit beta target
Sarilumab Low affinity immunoglobulin gamma Fc region receptor III-B target
Sarilumab Low affinity immunoglobulin gamma Fc region receptor III-A target
Sarilumab Low affinity immunoglobulin gamma Fc region receptor II-b target
Sarilumab Low affinity immunoglobulin gamma Fc region receptor II-a target
Sarilumab High affinity immunoglobulin gamma Fc receptor I target
Sarilumab Interleukin-6 receptor subunit alpha target
Sarilumab Cytochrome P450 3A4 enzyme
Satralizumab Interleukin-6 receptor subunit alpha target
Secukinumab Interleukin-17A target
Selicrelumab Tumor necrosis factor receptor superfamily member 5 target
Semzuvolimab T-cell surface glycoprotein CD4 target
Senlizumab Tumor necrosis factor target
Seribantumab Receptor tyrosine-protein kinase erbB-3 target
Setrusumab Sclerostin target
Sibeprenlimab Tumor necrosis factor ligand superfamily member 13 target
Sibrotuzumab Prolyl endopeptidase FAP target
Sifalimumab Interferon alpha-2 target
Siltuximab Cytochrome P450 3A4 enzyme
Siltuximab Interleukin-6 target
Simtuzumab Lysyl oxidase homolog 2 target
Sintilimab Programmed cell death protein 1 target
Sipavibart Spike glycoprotein target
Siplizumab T-cell surface antigen CD2 target
Sirukumab Interleukin-6 target
Sofituzumab vedotin Mucin-16 target
Solanezumab Amyloid-beta precursor protein target
Solitomab T-cell surface glycoprotein CD3 target
Solitomab Epithelial cell adhesion molecule target
Sonelokimab Interleukin-17F target
Sonelokimab Interleukin-17A target
Sotatercept Inhibin beta A chain target
Sotatercept Growth/differentiation factor 8 target
Sotatercept Growth/differentiation factor 11 target
Sotatercept Activin receptor type-1B target
Sotatercept Activin receptor type-2A target
Sotigalimab Tumor necrosis factor receptor superfamily member 5 target
Sotrovimab Spike glycoprotein target
Spartalizumab Programmed cell death protein 1 target
Spesolimab Interleukin-1 receptor-like 2 target
Stamulumab Growth/differentiation factor 8 target
Sugemalimab Programmed cell death 1 ligand 1 target
Sutimlimab Complement C1s subcomponent target
Tabalumab Tumor necrosis factor ligand superfamily member 13B target
Tafasitamab B-lymphocyte antigen CD19 target
Talacotuzumab Interleukin-3 receptor subunit alpha target
Talizumab Immunoglobulin heavy constant epsilon target
Talizumab High affinity immunoglobulin epsilon receptor subunit alpha target
Talquetamab G protein-coupled receptor family C group 5 member D target
Talquetamab T-cell surface glycoprotein CD3 target
Tanezumab Beta-nerve growth factor target
Tarextumab Neurogenic locus notch homolog protein 3 target
Tarextumab Neurogenic locus notch homolog protein 2 target
Tarlatamab T-cell surface glycoprotein CD3 target
Tarlatamab Delta-like protein 3 target
TB-402 Coagulation factor VIII target
Tb-403 Placenta growth factor target
Technetium Tc-99m arcitumomab Cell adhesion molecule CEACAM5 target
Technetium Tc-99m arcitumomab Cell adhesion molecule CEACAM1 target
Technetium Tc-99m nofetumomab merpentan B-lymphocyte antigen CD20 target
Technetium Tc-99m nofetumomab merpentan Epithelial cell adhesion molecule target
Teclistamab T-cell surface glycoprotein CD3 target
Teclistamab Tumor necrosis factor receptor superfamily member 17 target
Telisotuzumab Hepatocyte growth factor receptor target
Telisotuzumab vedotin Hepatocyte growth factor receptor target
Telisotuzumab vedotin ATP-binding cassette sub-family B member 5 transporter
Telisotuzumab vedotin Cytochrome P450 3A5 enzyme
Telisotuzumab vedotin Cytochrome P450 3A4 enzyme
Temelimab Syncytin-1 target
Teplizumab T-cell surface glycoprotein CD3 epsilon chain target
Teprotumumab Insulin-like growth factor 1 receptor target
Tesidolumab Complement C5 target
Tetanus immune globulin, human Tetanus toxin target
Tetulomab tetraxetan Lu-177 Leukocyte antigen CD37 target
Tezepelumab Thymic stromal lymphopoietin target
Theralizumab T-cell-specific surface glycoprotein CD28 target
Tibulizumab Interleukin-17A target
Tibulizumab Tumor necrosis factor ligand superfamily member 13B target
Tigatuzumab Tumor necrosis factor receptor superfamily member 10B target
Tilavonemab Microtubule-associated protein tau target
Tildrakizumab Interleukin-37 target
Tildrakizumab Interleukin-23 subunit alpha target
Tildrakizumab Cytochrome P450 4A11 enzyme
Tildrakizumab Interleukin-23 target
Timolumab Amine oxidase [copper-containing] 3 target
Tiragolumab T-cell immunoreceptor with Ig and ITIM domains target
Tislelizumab Programmed cell death protein 1 target
Tisotumab vedotin Cytochrome P450 3A4 enzyme
Tisotumab vedotin Tissue factor target
Tisotumab vedotin ATP-dependent translocase ABCB1 transporter
Tixagevimab Spike glycoprotein target
TJ003234 Granulocyte-macrophage colony-stimulating factor target
Tocilizumab Interleukin-6 receptor subunit alpha target
Tocilizumab Cytochrome P450 3A4 enzyme
Tocilizumab Interleukin-6 receptor subunit beta target
Tocilizumab Interleukin-6 target
Tomaralimab Toll-like receptor 2 target
Tomuzotuximab Epidermal growth factor receptor target
Toralizumab CD40 ligand target
Toripalimab Programmed cell death protein 1 target
Tositumomab Low affinity immunoglobulin gamma Fc region receptor II-b target
Tositumomab B-lymphocyte antigen CD20 target
Tositumomab I-131 Low affinity immunoglobulin gamma Fc region receptor II-b target
Tositumomab I-131 B-lymphocyte antigen CD20 target
Tovetumab Platelet-derived growth factor receptor alpha target
Tralokinumab Interleukin-13 target
Trastuzumab Receptor tyrosine-protein kinase erbB-2 target
Trastuzumab deruxtecan Cathepsin B enzyme
Trastuzumab deruxtecan Receptor tyrosine-protein kinase erbB-2 target
Trastuzumab deruxtecan Broad substrate specificity ATP-binding cassette transporter ABCG2 transporter
Trastuzumab deruxtecan ATP-binding cassette sub-family C member 1 transporter
Trastuzumab deruxtecan Solute carrier organic anion transporter family member 1B3 transporter
Trastuzumab deruxtecan ATP-dependent translocase ABCB1 transporter
Trastuzumab deruxtecan High affinity immunoglobulin gamma Fc receptor I target
Trastuzumab deruxtecan Solute carrier organic anion transporter family member 1B1 transporter
Trastuzumab deruxtecan Procathepsin L enzyme
Trastuzumab deruxtecan Cytochrome P450 3A4 enzyme
Trastuzumab deruxtecan Multidrug and toxin extrusion protein 2 transporter
Trastuzumab deruxtecan DNA topoisomerase 1 target
Trastuzumab deruxtecan Lysosomal alpha-glucosidase enzyme
Trastuzumab deruxtecan DNA topoisomerase 1 enzyme
Trastuzumab duocarmazine Receptor tyrosine-protein kinase erbB-2 target
Trastuzumab emtansine Cytochrome P450 3A5 enzyme
Trastuzumab emtansine Cytochrome P450 3A4 enzyme
Trastuzumab emtansine ATP-dependent translocase ABCB1 transporter
Trastuzumab emtansine Receptor tyrosine-protein kinase erbB-2 target
Tregalizumab T-cell surface glycoprotein CD4 target
Tremelimumab Cytotoxic T-lymphocyte protein 4 target
Tucotuzumab celmoleukin Epithelial cell adhesion molecule target
Tusamitamab ravtansine Cell adhesion molecule CEACAM5 target
Ublituximab B-lymphocyte antigen CD20 target
Ulocuplumab C-X-C chemokine receptor type 4 target
Upanovimab Spike glycoprotein target
Urelumab Tumor necrosis factor receptor superfamily member 9 target
Urtoxazumab Orf protein target
Ustekinumab Peptide deformylase, mitochondrial target
Ustekinumab Interleukin-12 subunit alpha target
Ustekinumab Interleukin-23 subunit alpha target
Ustekinumab Interleukin-23 target
Ustekinumab Interleukin-12 subunit beta target
Utomilumab Tumor necrosis factor receptor superfamily member 9 target
Vadastuximab talirine Myeloid cell surface antigen CD33 target
Valanafusp alfa Alpha-L-iduronidase target
Valanafusp alfa Insulin receptor target
Vanucizumab Angiopoietin-2 target
Vanucizumab Vascular endothelial growth factor A, long form target
Varlilumab CD27 antigen target
Vatelizumab Integrin alpha-2 target
Vedolizumab Integrin beta-7 target
Vedolizumab Integrin alpha-4 target
Veligrotug Insulin-like growth factor 1 receptor target
Veltuzumab B-lymphocyte antigen CD20 target
Vesencumab Neuropilin-1 target
Vilobelimab Complement C5 target
Visilizumab T-cell surface glycoprotein CD3 epsilon chain target
Vobarilizumab Interleukin-6 receptor subunit alpha target
Vofatamab Fibroblast growth factor receptor 3 target
Volagidemab Glucagon receptor target
Volociximab Integrin alpha-5 target
Volociximab Fibronectin receptor target
Vonlerolizumab Tumor necrosis factor receptor superfamily member 4 target
Vopratelimab Inducible T-cell costimulator target
Vorsetuzumab mafodotin CD70 antigen target
Vunakizumab Interleukin-17A target
XAV-19 Spike glycoprotein target
Xentuzumab Insulin-like growth factor 2 target
Xentuzumab Insulin-like growth factor 1 target
XmAb 2513 Tumor necrosis factor receptor superfamily member 8 target
Zalutumumab Epidermal growth factor receptor target
Zanidatamab Receptor tyrosine-protein kinase erbB-2 target
Zanolimumab T-cell surface glycoprotein CD4 target
Zansecimab Angiopoietin-2 target
Zenocutuzumab Receptor tyrosine-protein kinase erbB-3 target
Zenocutuzumab Receptor tyrosine-protein kinase erbB-2 target
Zilovertamab Inactive tyrosine-protein kinase transmembrane receptor ROR1 target
Ziltivekimab Interleukin-6 target
Zimberelimab Programmed cell death protein 1 target
Zolbetuximab Claudin-18 target

Drug	Drug Description
Abagovomab	Abagovomab is under investigation in clinical trial NCT00418574 (Efficacy Multicentre Trial of Immunotherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients).
Abatacept	A disease-modifying antirheumatic drug (DMARD) used in the management of rheumatic conditions, such as rheumatoid or psoriatic arthritis, and for the prophylaxis of acute graft-versus-host disease.
Abciximab	A monoclonal anti-glycoprotein IIb/IIIa receptor antibody used to prevent thrombosis during percutaneous coronary intervention.
Abelacimab	Abelacimab is under investigation in clinical trial NCT04755283 (Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation).
Abituzumab	Abituzumab has been used in trials studying the treatment of Prostate Cancer Metastatic.
Abrilumab	Abrilumab is under investigation in clinical trial NCT01290042 (Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.).
Acimtamig	Acimtamig is a tetravalent bispecific chimeric anti-human CD30 x anti-human CD16A recombinant antibody construct.
Actoxumab	Actoxumab is under investigation in clinical trial NCT01241552 (A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)).
Adakitug	Investigated for use/treatment in autoimmune diseases and inflammatory disorders (unspecified).
Adalimumab	A monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.
Adecatumumab	Investigated for use/treatment in breast cancer and prostate cancer.
Aducanumab	A monoclonal antibody indicated in the treatment of Alzheimer's disease.
Afelimomab	Investigated for use/treatment in sepsis and septicemia.
AGS-16C3F	AGS 16C3F is an intravenously administered, anti-ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) antibody-drug conjugate. AGS-16C3F is under investigation in clinical trial NCT02639182 (A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell...
Alefacept	A recombinant fusion protein that binds CD2 and is used treat moderate to severe plaque psoriasis.
Alemtuzumab	A monoclonal anti-CD52 antibody used in the treatment of B-cell chronic lymphocytic leukemia and relapsing forms of multiple sclerosis.
Alirocumab	A PCSK9 inhibitor used as an adjunct to manage heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in patients who require additional lowering of LDL-cholesterol (LDL-C).
Alpha-1-proteinase inhibitor	A purified form of human alpha-1 proteinase inhibitor used to treat emphysema patients with associated alpha-1 proteinase inhibitor deficiency.
Amatuximab	Amatuximab has been used in trials studying the treatment and basic science of Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Pancreatic Cancer, and Mesothelioma, Malignant, among others.
AMG 108	Investigated for use/treatment in osteoarthritis and rheumatoid arthritis.
Amivantamab	An EGF and MET receptor targeted antibody indicated in the treatment of non-small cell lung cancer with an EGFR 20 exon insertion mutation.
Amubarvimab	Amubarvimab (BRII-196) was under investigation in clinical trials (NCT04691180 and NCT04787211) to treat COVID-19, focusing on its safety, tolerability, and efficacy.
Andecaliximab	GS-5745 has been used in trials studying the treatment of Tumors, Breast Cancer, Crohn's Disease, Colorectal Cancer, and Pancreatic Cancer, among others.
Anetumab ravtansine	Anetumab ravtansine is under investigation in clinical trial NCT03455556 (Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer).
Anifrolumab	A monoclonal antibody that inhibits type 1 interferon receptors, indicated in the treatment of moderate to severe systemic lupus erythematosus.
Anrukinzumab	Anrukinzumab has been used in trials studying the diagnostic of Asthma.
Ansuvimab	A fully human monoclonal IgG1 antibody directed against the GP1,2 surface protein of Zaire ebolavirus that is an effective treatment for Ebola virus disease.
Anthrax immune globulin human	An immunizing agent used for the treatment of inhalational anthrax in adult and pediatric patients in combination with antibacterial agents.
Anti-SARS-CoV-2 immunoglobulin	Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) is obtained from the plasma of patients who recover from COVID-19 and develop neutralizing antibodies. Anti-coronavirus immunoglobulin is derived from COVID-19 convalescent plasma(https://go.drugbank.com/drugs/DB15692) but contains...
Anti-SARS-CoV-2 REGN-COV2	Anti-SARS-COV-2 REGN-COV2 is a combination of novel antibodies designed by Regeneron for both the prevention and treatment of SARS-COV-2, the virus that causes COVID-19. This drug is a combination of...
Antilymphocyte immunoglobulin (horse)	A primarily IgG immune globulin used to manage allograft rejection in renal transplant patients.
Antithrombin III human	An alpha-2-glycoprotein used to prevent thromboembolisms in patients with hereditary antithrombin III deficiency.
Antithymocyte immunoglobulin (rabbit)	A purified form of rabbit anti-thymocyte antibodies used for immunosuppression in patients receiving kidney transplants.
Anvatabart opadotin	Not Annotated
Apitegromab	Apitegromab is under investigation in clinical trial NCT03921528 (An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy).
Apolizumab	Investigated for use/treatment in lymphoma (non-hodgkin's), leukemia (lymphoid), and solid tumors.
Apomab	Apomab is under investigation in clinical trial NCT00851136 (A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and...
Aprutumab ixadotin	Not Annotated
Arcitumomab	Not Annotated
Ascrinvacumab	Ascrinvacumab has been used in trials studying the treatment and basic science of Neoplasms, Advanced Solid Tumors, Carcinoma, Hepatocellular, and Malignant Pleural Mesothelioma.

Serum Globulins

Create a free account or log in to explore the full data card.